



QY 241 TGTGATTCCTCATATCAACTTATTTGTGACGATTTGATTTTAAATAATCTGACAA 300  
Db 241 TGTGATTCCTCATATCAACTTATTTGTGACGATTTGATTTTAAATAATCTGACAA 300  
QY 301 GAAGCATCTTTCATGATATGACAGGGGATAGCCCACTCATGTTCTGTACTGAATC 360  
Db 301 GAAGCATCTTTCATGATATGACAGGGGATAGCCCACTCATGTTCTGTACTGAATC 360  
QY 361 TCAACAGACACTGTTTATAAATGTGATCACTAATATGACAACCACTCCAGAGTCTCTT 420  
Db 361 TCAACAGACACTGTTTATAAATGTGATCACTAATATGACAACCACTCCAGAGTCTCTT 420  
QY 421 CCAAACTCTCAGGTTTTCCCTGCGGTGGTAAATCATGACTAATGGCCACAGATCAACTG 480  
Db 421 CCAAACTCTCAGGTTTTCCCTGCGGTGGTAAATCATGACTAATGGCCACAGATCAACTG 480  
QY 481 TCTGTAGTCAACCAAGTGTACATGCAGTAAACCTCTGGAACCATGGCTAGAT 540  
Db 481 TCTGTAGTCAACCAAGTGTACATGCAGTAAACCTCTGGAACCATGGCTAGAT 540  
QY 541 GAAGAACCTATTAGTACTTTAAGGAAAGGTGTTTATTTCACAGAAAGTTACAACCTAAT 600  
Db 541 GAAGAACCTATTAGTACTTTAAGGAAAGGTGTTTATTTCACAGAAAGTTACAACCTAAT 600  
QY 601 CCAAACTTTAGGATCATGACTTAACAACAACAACTTGTACTACGGCCCAATATATGACA 660  
Db 601 CCAAACTTTAGGATCATGACTTAACAACAACAACTTGTACTACGGCCCAATATATGACA 660  
QY 661 CTGAACAAGACTGACCCAGCCAACTGTTGAATGGCTAGAAAGTACATTGAACCACTCT 720  
Db 661 CTGAACAAGACTGACCCAGCCAACTGTTGAATGGCTAGAAAGTACATTGAACCACTCT 720  
QY 721 CAGCAGAATAAGAGAAGGTGTATATCATAGACATGTTCCAGTGGGTATCTGCCATCT 780  
Db 721 CAGCAGAATAAGAGAAGGTGTATATCATAGACATGTTCCAGTGGGTATCTGCCATCT 780  
QY 781 TCACAGAACATCACAGCAATGAGAGATACTATATGAGAAATTGATAGATTTTTCAA 840  
Db 781 TCACAGAACATCACAGCAATGAGAGATACTATATGAGAAATTGATAGATTTTTCAA 840  
QY 841 AAATACAGTGTATGTCATTGACAGCAATTTTATGACACACTCACAAGACAGCATTTATG 900  
Db 841 AAATACAGTGTATGTCATTGACAGCAATTTTATGACACACTCACAAGACAGCATTTATG 900  
QY 901 GTTCTTTTCAGATTAATAAAGGAAGTCCAGTAAATCTTTGTTGTGGCTCCTGCTGTACA 960  
Db 901 GTTCTTTTCAGATTAATAAAGGAAGTCCAGTAAATCTTTGTTGTGGCTCCTGCTGTACA 960  
QY 961 CCAGTGAAGAGTGTTTTAGAAAAAGCAAGCAACATCCTGGTATCAGACTGTTTCAGTAT 1020  
Db 961 CCAGTGAAGAGTGTTTTAGAAAAAGCAAGCAACATCCTGGTATCAGACTGTTTCAGTAT 1020  
QY 1021 GATCCTCGTATTTATAATTTATGATATGTTGACAGTATTTACTGAACTGACAGAGCG 1080  
Db 1021 GATCCTCGTATTTATAATTTATGATATGTTGACAGTATTTACTGAACTGACAGAGCG 1080  
QY 1081 AATCTAAAGGAGAGTCCATCTGGAAGCTGAGTATATCCTGACCCAGACCTACGACAT 1140  
Db 1081 AATCTAAAGGAGAGTCCATCTGGAAGCTGAGTATATCCTGACCCAGACCTACGACAT 1140  
QY 1141 GAAGATTTGCAAGCCGGAAGTTTATATGATTAAGCTAAACAATTTACAATCCTAGACAGT 1200  
Db 1141 GAAGATTTGCAAGCCGGAAGTTTATATGATTAAGCTAAACAATTTACAATCCTAGACAGT 1200  
QY 1201 AAGCAGTTTATAAATACTACAAATTACTTCTTGTGAGTTATGACAGCAGTGAACATGT 1260  
Db 1201 AAGCAGTTTATAAATACTACAAATTACTTCTTGTGAGTTATGACAGCAGTGAACATGT 1260  
QY 1261 GATTAAGACATGTAAGGCTTTACAGATTGTGCAATTAATGAATCTGATAATATTTCTAT 1320  
Db 1261 GATTAAGACATGTAAGGCTTTACAGATTGTGCAATTAATGAATCTGATAATATTTCTAT 1320

QY 1321 GCAGATGCTCTCAACAGCCTTATATATAAAGCACAAATTACTAG 1362  
Db 1321 GCAGATGCTCTCAACAGCCTTATATATAAAGCACAAATTACTAG 1362

RESULT 2  
BC018999  
LOCUS  
DEFINITION  
Homo sapiens sphingomyelin phosphodiesterase, acid-like 3A, mRNA  
(CDNA clone MGC:20681 IMAGE:313813), complete cds.  
BC018999  
KEYWORDS  
MGC.  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS  
1 (bases 1 to 1759)  
Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,  
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,  
Altschul, S.F., Zeeberg, B., Bueltow, K.H., Schaefer, C.F., Bhat, N.K.,  
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Heieh, F.,  
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,  
Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,  
Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,  
Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,  
Abramsen, R.D., Mullaby, S.J., Bosak, S.A., McEwan, P.J.,  
McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,  
Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,  
Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,  
Fahney, J., Helton, E., Ketterman, M., Madan, A., Rodrigues, S.,  
Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,  
Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,  
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,  
Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smailus, D.E.,  
Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.

TITLE  
human and mouse CDNA sequences  
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)  
12477932

JOURNAL  
PUBMED  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
2 (bases 1 to 1759)  
Strausberg, R.  
Direct Submission  
Submitted (07-DEC-2001) National Institutes of Health, Mammalian  
Gene Collection (MGC), Cancer Genomics Office, National Cancer  
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
USA

REMARK  
COMMENT  
NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
On Aug 19, 2003 this sequence version replaced gi:17512052.  
Contact: MGC help desk  
Email: [cgabs-r@mail.nih.gov](mailto:cgabs-r@mail.nih.gov)  
Tissue Procurement: ATCC

CDNA Library Preparation: Rubin Laboratory  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)  
DNA Sequencing by: National Institutes of Health Intramural  
Sequencing Center (NISC),  
Gaithersburg, Maryland;  
web site: <http://www.nisc.nih.gov/>  
Contact: [nisc\\_mgc@nhgri.nih.gov](mailto:nisc_mgc@nhgri.nih.gov)  
Akhter, N., Ayale, K., Beckstrom-Sternberg, S.M., Benjamin, B.,  
Blakesley, R.W., Bouffard, G.G., Breen, K., Brinkley, C., Brooks, S.,  
Dietrich, N.L., Granite, S., Guan, X., Gupta, J., Haghighi, P.,  
Hansen, N., Ho, S.-L., Karlins, B., Kwong, P., Latic, P., Legaspi, R.,  
Maduro, Q.L., Masiello, C., Maskeri, B., Mastrian, S.D., McCloskey, J.C.,  
McDowell, J., Pearson, R., Stantirip, S., Thomas, P.J., Touchman, J.W.,  
Tsurgon, C., Vogt, J.L., Walker, M.A., Wetherby, K.D., Wiggins, L.,  
Young, A., Zhang, L.-H. and Green, E.D.

Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/LNL at: <http://image.lnl.gov>  
Series: IRAL Plate: 30 Row: a Column: 7  
This clone was selected for full length sequencing because it  
passed the following selection criteria: matched mRNA gi: 24307910.

FEATURES	source	Location/Qualifiers
		1. 1759
		/organism="Homo sapiens"
		/mol_type="mRNA"
		/db_xref="taxon:9606"
		/clone="MGC:20681 IMAGE:3138813"
		/tissue_type="Placenta, chorlocarcinoma"
		/clone_id="NIH MGC_21"
		/lab_host="DH10B-R"
		/note="Vector: pOTB7"
gene		1. 1759
		/gene="SMPDL3A"
		/note="synonyms: ASM3A, FLJ20177, ASML3a, YR36GH4.1"
		/db_xref="locusid:10924"
CDS		69. 1430
		/gene="SMPDL3A"
		/codon_start=1
		/product="acid sphingomyelinase-like phosphodiesterase 3A"
		/protein_id="AAH18999.1"
		/db_xref="GI:17512053"
		/db_xref="locusid:10924"
		/translation="MALVRLAVCCLLTAMHGRSGLGLPVAPAGGRNPPEAIGQFWHT DLHLDPYTHITDDHTKVCASSKGANASNPGEFGLVCDSPYQILISAFDFIKNSGOEA SEMIWTGDSPPHVPPELSTDTVINVTNNWTTIQLSPNLQVFPALGNHDYWPQDL PVVTSKYNAVANLWKPWLDEEALSTLRKGFFYSQKVTNPNLRIISLNTNLYGPN MTLNKTDPANOFEMLESTLNNQQNKEKYIIAHVPVGYLPSSQNTAMREYNEKLI DIFOKYSDVLAGQFYGHTHRSIMVLSDKGSPPNSLFPAPATPVKSLYEKOTNPG IRLFQYDPRDYKLLDMLQYYLNLTEANLKGESIMKLEYILTQTYDIEDLQPESLYGLA KQFTILDSKQFIKYNNYFVSVSDSVTCDKTCKAFQICAIMNLDNISVADCLQLYIK HNY"

## ORIGIN

	Query Match	99.9%	Score 1360.4;	DB 9;	Length 1759;	
	Best Local Similarity	99.9%;	Pred. No. 0;			
	Matches 1361;	Conservative	0;	Mismatches	1;	Indels 0; Gaps 0;
Qy	1	ATGGCGCTGTGCGCGCACTGCTGTCGTCGCTGACTGCCTGGCACTGCCGCTCCGGC	60			
Db	69	ATGGCGCTGTGCGCGCACTGCTGTCGTCGCTGACTGCCTGGCACTGCCGCTCCGGC	128			
Qy	61	CTCGGGCTGCCGTCGGCCCCGAGCGCGCAGAAATCTTCCGGCATAGACAGTTT	120			
Db	129	CTCGGGCTGCCGTCGGCCCCGAGCGCGCAGAAATCTTCCGGCATAGACAGTTT	188			
Qy	121	TGGCATGTGACTGACTTAACCTTAGACCCTACTTACCACATCACAGATGACCAAAAA	180			
Db	189	TGGCATGTGACTGACTTAACCTTAGACCCTACTTACCACATCACAGATGACCAAAAA	248			
Qy	181	GTCGTGCTTCATCTAAGAAGTGCAAATGCCCTCCAACCTGGCCCTTTGGAGATGTTCTG	240			
Db	249	GTCGTGCTTCATCTAAGAAGTGCAAATGCCCTCCAACCTGGCCCTTTGGAGATGTTCTG	308			
Qy	241	TGTGATTCTCCATATCACTTATTTGTGAGCATTTGATTTATAAAAATTCGACA	300			
Db	309	TGTGATTCTCCATATCACTTATTTGTGAGCATTTGATTTATAAAAATTCGACA	368			
Qy	301	GAAGCATCTTTCATGATATGACAGGGGATAGCCCACTCATGTTCCGTGACCTGA	360			
Db	369	GAAGCATCTTTCATGATATGACAGGGGATAGCCCACTCATGTTCCGTGACCTGA	428			
Qy	361	TCAACAGACACTGTTATAATGTGATCACTAATATGACCAACCATCCAGATCTTTT	420			
Db	429	TCAACAGACACTGTTATAATGTGATCACTAATATGACCAACCATCCAGATCTTTT	488			
Qy	421	CCAATCTCCAGTTTTCCCTGCGCTGGGTAATCATGACTATTTGGCCACAGATCACTG	480			
Db	489	CCAATCTCCAGTTTTCCCTGCGCTGGGTAATCATGACTATTTGGCCACAGATCACTG	548			
Qy	481	TCTGTAGTCAACCAAGTAAGTGTACAATGCAGTAGCAAACTCTGGAAACCATGGCTAGAT	540			
Db	549	CCTGTAGTCAACCAAGTAAGTGTACAATGCAGTAGCAAACTCTGGAAACCATGGCTAGAT	608			
Qy	541	GAAGAAGCTATTAGTACTTTAAGGAAAGGTGTTTATTCACAGAAAGTTACAATAAT	600			

Db	609	GAAGA	GC	TAT	TAG	TACT	TAA	GAA	AG	TGG	TTT	TAT	TAC	A	GAA	AG	TTA	CA	A	CT	AAT	668	
Qy	601	CCAAC	CT	TAG	AT	CA	T	CA	GT	CT	AA	A	CA	CA	AA	CT	TT	G	T	A	CT	A	660
Db	669	CCAAAC	CT	TAG	AT	CA	T	CA	GT	CT	AA	A	CA	CA	AA	CT	TT	G	T	A	CT	A	728
Qy	661	CTGAAC	A	G	A	C	T	G	A	C	C	C	A	G	C	C	A	A	C	C	A	G	720
Db	729	CTGAAC	A	G	A	C	T	G	A	C	C	C	A	G	C	C	A	A	C	C	A	G	788
Qy	721	CAGCAG	A	T	A	A	G	A	G	A	G	T	G	T	A	T	A	T	A	T	A	T	780
Db	789	CAGCAG	A	T	A	A	G	A	G	T	G	T	A	T	A	T	A	T	A	T	A	T	848
Qy	781	TCACAG	A	C	A	T	C	A	C	A	G	A	T	G	A	G	A	T	A	T	A	T	840
Db	849	TCACAG	A	C	A	T	C	A	C	A	G	A	T	G	A	G	A	T	A	T	A	T	908
Qy	841	AAATAC	A	G	T	G	T	C	A	T	T	G	C	A	G	A	C	A	A	T	T	A	900
Db	909	AAATAC	A	G	T	G	T	C	A	T	T	G	C	A	G	A	C	A	A	T	T	A	968
Qy	901	GTTCTT	C	A	G	A	T	A	A	A	A	A	A	A	A	A	A	A	A	A	A	960	
Db	969	GTTCTT	C	A	G	A	T	A	A	A	A	A	A	A	A	A	A	A	A	A	A	1028	
Qy	961	CCAGTG	A	G	A	G	T	G	T	T	A	G	A	A	A	A	A	A	A	A	A	1020	
Db	1029	CCAGTG	A	G	A	G	T	G	T	T	A	G	A	A	A	A	A	A	A	A	A	1088	
Qy	1021	GATCCT	C	G	T	A	T	A	T	A	A	T	T	A	T	T	G	A	T	A	T	1080	
Db	1089	GATCCT	C	G	T	A	T	A	T	A	A	T	T	A	T	T	G	A	T	A	T	1148	
Qy	1081	AATCTA	A	A	G	G	A	G	A	G	T	C	A	T	C	T	G	A	A	G	T	1140	
Db	1149	AATCTA	A	A	G	G	A	G	A	G	T	C	A	T	C	T	G	A	A	G	T	1208	
Qy	1141	GAAGAT	T	T	G	C	A	G	C	C	G	A	A	G	T	T	A	T	A	T	A	1200	
Db	1209	GAAGAT	T	T	G	C	A	G	C	C	G	A	A	G	T	T	A	T	A	T	A	1268	
Qy	1201	AAGCAG	T	T	A	T	A	A	A	A	T	A	C	A	A	T	T	A	C	T	T	1260	
Db	1269	AAGCAG	T	T	A	T	A	A	A	A	T	A	C	A	A	T	T	A	C	T	T	1328	
Qy	1261	GATAAG	A	C	A	T	G	T	A	A	G	C	T	T	C	A	G	A	T	T	G	1320	
Db	1329	GATAAG	A	C	A	T	G	T	A	A	G	C	T	T	C	A	G	A	T	T	G	1388	
Qy	1321	GCAGAT	T	G	C	C	T	C	A	A	A	C	A	G	C	T	T	A	T	A	A	1362	
Db	1389	GCAGAT	T	G	C	C	T	C	A	A	A	C	A	G	C	T	T	A	T	A	A	1430	

RESULT 3	
AK000184	
LOCUS	
DEFINITION	AK000184 1760 bp mRNA linear PRI 13-SEP-2003
	Homo sapiens cDNA FLJ20177 fis, clone COL09966, highly similar to
	Y08136 H.
ACCESSION	AK000184
VERSION	AK000184.1 GI:7020103
KEYWORDS	oligo capping; fis (full insert sequence).
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
	Mammalia; Eutheria; Primates; Catarrhini; Homiinae; Homo.
REFERENCE	1
AUTHORS	Kawabata, A., Hikiji, T., Kobatake, N., Inagaki, H., Ikema, Y., Okamoto, S., Okitani, R., Ota, T., Suzuki, Y., Obayashi, M., Nishi, T., Shibahara, T., Tanaka, T., Nakamura, Y., Isogai, T. and Sugano, S.
TITLE	NEDO human cDNA sequencing project





Query Match	99.9%	Score 1360.4;	DB 6;	Length 1764;
Best Local Similarity	99.9%;	Pred. No. 0;		
Matches 1361; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

QY	1	ATGGCGCTGTGTGCGGCACCTCGTCTGCTGCCCTGTGACTGCTGGCACTGCCGCTCCGGC	60
Db	69	ATGGCGCTGTGTGCGGCACCTCGTCTGCTGCCCTGTGACTGCTGGCACTGCCGCTCCGGC	128
QY	61	CTCGGGCTGCCGCTGGCGCCCGCAGCGCGCAGGAATCTCTCCGGCATAGGACAGTTT	120
Db	129	CTCGGGCTGCCGCTGGCGCCCGCAGCGCGCAGGAATCTCTCCGGCATAGGACAGTTT	188
QY	121	TGGCATGTGACTGACTTACACTTAGACCCCTACTTACCAACATGACAGATGACCACAAAA	180
Db	189	TGGCATGTGACTGACTTACACTTAGACCCCTACTTACCAACATGACAGATGACCACAAAA	248
QY	181	GTGTGTGCTTCATCTAAAGGTGCAAAATGCCCTCCAAACCCTGGCCCTTTTGAGATGTTCTG	240
Db	249	GTGTGTGCTTCATCTAAAGGTGCAAAATGCCCTCCAAACCCTGGCCCTTTTGAGATGTTCTG	308
QY	241	TGTGATTTCTCCATATCAACTTATTTTGTGACGATTTGATTTTATTTAAATTTCTGGACAA	300
Db	309	TGTGATTTCTCCATATCAACTTATTTTGTGACGATTTGATTTTATTTAAATTTCTGGACAA	368
QY	301	GAAGCATCTTTCATGATATGACAGGGGATAGCCCACTCATGTTCCTGTACTGTAAGTTC	360
Db	369	GAAGCATCTTTCATGATATGACAGGGGATAGCCCACTCATGTTCCTGTACTGTAAGTTC	428
QY	361	TCAACAGACACTGTTATTAATGTGATCACTAATATGACAAACCATCCAGAGTCTCTTT	420
Db	429	TCAACAGACACTGTTATTAATGTGATCACTAATATGACAAACCATCCAGAGTCTCTTT	488
QY	421	CCAAATCTCCAGGTTTTCCTGCGCTGGGTAATCATGACTTATGGCCACAGATCAACTG	480
Db	489	CCAAATCTCCAGGTTTTCCTGCGCTGGGTAATCATGACTTATGGCCACAGATCAACTG	548
QY	481	TCTGTAGTCAACCAGTAAAGTGTAACAATGACAGTAGCAAAACCTTGAAAAACCATGGCTAGT	540
Db	549	CCTGTAGTCAACCAGTAAAGTGTAACAATGACAGTAGCAAAACCTTGAAAAACCATGGCTAGT	608
QY	541	GAAGAAGCTATTAGTACTTTAAGAAAGGTGTTTTTATTCACAGAAAGTTACAACATAAT	600
Db	609	GAAGAAGCTATTAGTACTTTAAGAAAGGTGTTTTTATTCACAGAAAGTTACAACATAAT	668
QY	601	CCAAACCTTAGGATCATCAGTCTAACAACAACAACTTGTACTACGGCCCAATATTAATGACA	660
Db	669	CCAAACCTTAGGATCATCAGTCTAACAACAACAACTTGTACTACGGCCCAATATTAATGACA	728
QY	661	CTGAACAAGACTGACCCAGCCAAACCAAGTTTGAATGGCTAGAAAGTACATTGAACAACCTCT	720
Db	729	CTGAACAAGACTGACCCAGCCAAACCAAGTTTGAATGGCTAGAAAGTACATTGAACAACCTCT	788
QY	721	CAGCAGAATTAAGGAAAGTGTAATCATAGCACATGTTCCAGTGGGGTATCTGCCATCT	780
Db	789	CAGCAGAATTAAGGAAAGTGTAATCATAGCACATGTTCCAGTGGGGTATCTGCCATCT	848
QY	781	TCACAGAATCATCACAGCAATGAGAAATACTATTAATGAGAAATTGATAGATATTTTCAA	840
Db	849	TCACAGAATCATCACAGCAATGAGAAATACTATTAATGAGAAATTGATAGATATTTTCAA	908
QY	841	AAATACAGTATGTATTCAGGACCAATTTTATGACACACTCACAGAGACAGCATTAATG	900
Db	909	AAATACAGTATGTATTCAGGACCAATTTTATGACACACTCACAGAGACAGCATTAATG	968
QY	901	GTTCTTTACAGTAAAAAGAAAGTCCAGTAAATTTCTTTGTTGTGGCTCCTGCTGTTACA	960
Db	969	GTTCTTTACAGTAAAAAGAAAGTCCAGTAAATTTCTTTGTTGTGGCTCCTGCTGTTACA	1028
QY	961	CCAAGTGAAGAGTGTTTTAAAGAAAACAGACCAACAATCTCTGTAATCAGACTGTTTCAAGTAT	1020
Db	1029	CCAAGTGAAGAGTGTTTTAAAGAAAACAGACCAACAATCTCTGTAATCAGACTGTTTCAAGTAT	1088

OY	1021	GATCCTCGTATTATAAATTATTGGATATGTTGCAGTATTACTTGAATCTGACAGAGCGG	1080
Db	1089	GATCCTCGTATTATAAATTATTGGATATGTTGCAGTATTACTTGAATCTGACAGAGCGG	1148
OY	1081	AATCTAAAGGAGAGTCATCTGGAAGCTGGAGTATATCCCTGACCAGACCTTAGCAATT	1140
Db	1149	AATCTAAAGGAGAGTCATCTGGAAGCTGGAGTATATCCCTGACCAGACCTTAGCAATT	1208
OY	1141	GAAGATTTGCAGCCGGAAGTTTATATGATTAGCTAAACAATTTACAATCCTAGACAGT	1200
Db	1209	GAAGATTTGCAGCCGGAAGTTTATATGATTAGCTAAACAATTTACAATCCTAGACAGT	1268
OY	1201	AAGCAGTTTATAAATACTACAAATTACTCTTGAGTTATGACAGCAGTGTAACATGT	1260
Db	1269	AAGCAGTTTATAAATACTACAAATTACTCTTGAGTTATGACAGCAGTGTAACATGT	1328
OY	1261	GATAAGACATGTAAAGCCTTTCAGATTGTGCAATTATGAATCTTGATAATATTTCCAT	1320
Db	1329	GATAAGACATGTAAAGCCTTTCAGATTGTGCAATTATGAATCTTGATAATATTTCCAT	1388
OY	1321	GCAGATTGCCCTCAAACAGCTTTATATTAAGCACAAATTACTAG	1362
Db	1389	GCAGATTGCCCTCAAACAGCTTTATATTAAGCACAAATTACTAG	1430

RESULT 5			
AR280051			
LOCUS	AR280051	1764 bp	DNA
DEFINITION	Sequence 13 from patent	US 6518029.	linear
ACCESSION	AR280051		
VERSION	AR280051.1	GI:29715400	
KEYWORDS			
SOURCE	Unknown.		

REFERENCE AUTHORS	TITLE JOURNAL
1 (bases 1 to 1764) Bandman, O., Lal, P., Hillman, J. L., Corley, N. C., Guegler, K. J. and Shah, P.	Human hydrolase-like molecules Patent: US 6518029-A 13 11-FEB-2003;

TITLE	Human hydrolase-like molecules
JOURNAL	Patent: US 6518029-A 13 11-FEB-2003;
FEATURES	Location/Qualifiers
source	1. 1764

```
/organism="unknown"  
/mol_type="genomic DNA"
```

## ORIGIN

Query Match	99.9%	Score 1360.4;	DB 6;	Length 1764;
Best Local Similarity	99.9%;	Pred. No. 0;		
Matches 1361; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

OY	I	ATGGCGCTGTTGCGCGCACTGTCTGCTGCCTGCTGACTGCTGGCAGTCCGCTCCGGC	60
Dp	69	ATTGCCCTGTGTGCGCGCACTGTCTGCTGCTGACTGCTGGCAGTCCGCTCCGGC	128
OY	61	CTCGGGCTGCCCGTGCGCGCAGGGCGGAGGAATCTCTCCGCGATAGGACAGTTT	120
Dp	129	CTCGGGCTGCCCGTGCGCGCAGGGCGGAGGAATCTCTCCGCGATAGGACAGTTT	188
OY	121	TGGCATGTGACTGACTTAACACTTAGACCCTACTTACCACATCACAGATGACCACAAAA	180
Dp	189	TGGCATGTGACTGACTTAACACTTAGACCCTACTTACCACATCACAGATGACCACAAAA	248
OY	181	GTTGTGTCTTCATCTTAAGGTGCAAAATGCCCTCCAACCCCTGGCCCTTTTGGAGATGTTCTG	240
Dp	249	GTTGTGTCTTCATCTTAAGGTGCAAAATGCCCTCCAACCCCTGGCCCTTTTGGAGATGTTCTG	308
OY	241	TGTGATTTCTCCATATCAACTTAATTTTGTACAGCATTTGATTTTAATAAAAATTCTGGACAA	300
Dp	309	TGTGATTTCTCCATATCAACTTAATTTTGTACAGCATTTGATTTTAATAAAAATTCTGGACAA	368
OY	301	GAAGCATCTTTTCATGATATGEGACAGGGGATAGCCCCACCTCATGTTCTGTACCTGAACCTC	360
Dp	369	GAAGCATCTTTTCATGATATGEGACAGGGGATAGCCCCACCTCATGTTCTGTACCTGAACCTC	428

QY	361	TCACAGACACTGTTATTAATGTGATCAGTAATATGACAAACCACCATCCAGAGTCTCTTT	420
Db	429	TCACAGACACTGTTATTAATGTGATCAGTAATATGACAAACCACCATCCAGAGTCTCTTT	488
QY	421	CCAAATCTCCAGGTTTTCCCTGCGTGGGTAAATCATGACTATTTGGCCACAGATCAACTG	480
Db	489	CCAAATCTCCAGGTTTTCCCTGCGTGGGTAAATCATGACTATTTGGCCACAGATCAACTG	548
QY	481	TCTGTAGTCACCAAGTGTACAATGACAGTAGCAAACTCTGAAAACCATGGCTAGAT	540
Db	549	CCTGTAGTCACCAAGTGTACAATGACAGTAGCAAACTCTGAAAACCATGGCTAGAT	608
QY	541	GAAGAAGCTATTAGTACTTTAAGAAAAGTGTTTTTAATTCACAGAAAGTTACAATAAT	600
Db	609	GAAGAAGCTATTAGTACTTTAAGAAAAGTGTTTTTAATTCACAGAAAGTTACAATAAT	668
QY	601	CCAAACCTTAGGATCATCACTCTAACAACAACAACTTGTACTACGGCCCAATATATGACA	660
Db	669	CCAAACCTTAGGATCATCACTCTAACAACAACAACTTGTACTACGGCCCAATATATGACA	728
QY	661	CTGAACAAGACTGACCCAGCCAAACAGTTGAAATGGCTAGAAAAGTACATTGAACAACCT	720
Db	729	CTGAACAAGACTGACCCAGCCAAACAGTTGAAATGGCTAGAAAAGTACATTGAACAACCT	788
QY	721	CAGCAGAATTAAGGAGAAAGTGTAATCATAGCACATGTTCCAGTGGGTATCTGCCATCT	780
Db	789	CAGCAGAATTAAGGAGAAAGTGTAATCATAGCACATGTTCCAGTGGGTATCTGCCATCT	848
QY	781	TCAACAACATCACAGCAATGAGAGAAATCTAATAATGAGAAATTGATAGATATTTTCAA	840
Db	849	TCAACAACATCACAGCAATGAGAGAAATCTAATAATGAGAAATTGATAGATATTTTCAA	908
QY	841	AAATACAGTGATGTCATTGACAGACAATTTTATGACACACTCACAGAGACAGATTAATG	900
Db	909	AAATACAGTGATGTCATTGACAGACAATTTTATGACACACTCACAGAGACAGATTAATG	968
QY	901	GTTCTTTCCAGATAAAAAAGAAAGTCCAGTAAATTTCTTGTGTGGCTCCTGCTGTACA	960
Db	969	GTTCTTTCCAGATAAAAAAGAAAGTCCAGTAAATTTCTTGTGTGGCTCCTGCTGTACA	1028
QY	961	CCAAGTGAAGAGTGTTTTAGAAAAACAGACCAACAATCCTGGTATCAGACTGTTCAATAT	1020
Db	1029	CCAAGTGAAGAGTGTTTTAGAAAAACAGACCAACAATCCTGGTATCAGACTGTTCAATAT	1088
QY	1021	GATCCTCGTATTAATAATTAATGGATATGTTGCAAGTAATTACTTGAATCTGACAGAGCG	1080
Db	1089	GATCCTCGTATTAATAATTAATGGATATGTTGCAAGTAATTACTTGAATCTGACAGAGCG	1148
QY	1081	AATCTAAAGGGAGAGTCCATCTGGAAGCTGGAGTATATCTGACCCAGACCTACGCATTT	1140
Db	1149	AATCTAAAGGGAGAGTCCATCTGGAAGCTGGAGTATATCTGACCCAGACCTACGCATTT	1208
QY	1141	GAAGATTTGAGCCGGAAGTTTATATGATTAGCTAAACAATTTCAATCTAGACAGT	1200
Db	1209	GAAGATTTGAGCCGGAAGTTTATATGATTAGCTAAACAATTTCAATCTAGACAGT	1268
QY	1201	AAGCAGTTTATAAATACTACAATTAATCTTGTGTGAGTTATGACAGCAGTGTAAAGT	1260
Db	1269	AAGCAGTTTATAAATACTACAATTAATCTTGTGTGAGTTATGACAGCAGTGTAAAGT	1328
QY	1261	GATAAGACATGTAAGGCTTTCAGATTTGTGCAATTATGAATCTTGATAATATTTCCAT	1320
Db	1329	GATAAGACATGTAAGGCTTTCAGATTTGTGCAATTATGAATCTTGATAATATTTCCAT	1388
QY	1321	GCAGATTGCTCAACAGCTTTATATAAAGCACAAATTACTAG 1362	
Db	1389	GCAGATTGCTCAACAGCTTTATATAAAGCACAAATTACTAG 1430	

RESULT 6	
AX281695	
LOCUS	AX281695
	1746 bp
	DNA
	linear
	PAT 02-NOV-2001

[illegible]



Query	Match	98.5%	Score 1341.4	DB 6	length 2505
Qy	720	TCAGCAGAAATTAAGGAGAGSTGTATATCATAGCACATGTTCCAGTGGGGTATCTGCCATC	779		
Db	789	TCAGCAGAAATTAAGGAGAGSTGTATATCATAGCACATGTTCCAGTGGGGTATCTGCCATC	848		
Qy	780	TTCAACAGAACATCACAGCAATGAGAGATCTATTAATGAGAAATTGATAGATATTTTCA	839		
Db	849	TTCAACAGAACATCACAGCAATGAGAGATCTATTAATGAGAAATTGATAGATATTTTCA	908		
Qy	840	AAAATACAGTGTATGCAATTCAGGACCAATTTTATGGACACCTCACAGAGACAGATTAT	899		
Db	909	AAAATACAGTGTATGCAATTCAGGACCAATTTTATGGACACCTCACAGAGACAGATTAT	968		
Qy	900	GGTCTTTTCAGATTAATAAGGAAAGTCCAGTAATCTTTGTTGTGGCTCCTGCTGTAC	959		
Db	969	GGTCTTTTCAGATTAATAAGGAAAGTCCAGTAATCTTTGTTGTGGCTCCTGCTGTAC	1028		
Qy	960	ACCACTGAAGAGTGTTTAGAAAAACAGACCAACAATCTGCTATCAGACTGTTTCAGTA	1019		
Db	1029	ACCACTGAAGAGTGTTTAGAAAAACAGACCAACAATCTGCTATCAGACTGTTTCAGTA	1088		
Qy	1020	TGATCCTCGTATTAATAATTATTTGATATGTTGCAGATTAATCTGAATCTGACAGAGC	1079		
Db	1089	TGATCCTCGTATTAATAATTATTTGATATGTTGCAGATTAATCTGAATCTGACAGAGC	1148		
Qy	1080	GAATCTAAAGGAGAGTCCATCTGGAAGCTGGAATATCTGACCCAGACCTTACGACAT	1139		
Db	1149	GAATCTAAAGGAGAGTCCATCTGGAAGCTGGAATATCTGACCCAGACCTTACGACAT	1208		
Qy	1140	TGAAGATTTGCAGCCGGAAGTTTATATGATTAGCTAAACAATTACAACTCTAGACAG	1199		
Db	1209	TGAAGATTTGCAGCCGGAAGTTTATATGATTAGCTAAACAATTACAACTCTAGACAG	1268		
Qy	1200	TAAAGCAGTTTATAAAATCTACAATTACTCTTTGTGAGTTATGACAGCAGTGTAAATG	1259		
Db	1269	TAAAGCAGTTTATAAAATCTACAATTACTCTTTGTGAGTTATGACAGCAGTGTAAATG	1328		
Qy	1260	TGATAAGACATGTAAAGGCTTTTCAGATTTGTGCAATTAATGAATCTTGATAATTTCTTA	1319		
Db	1329	TGATAAGACATGTAAAGGCTTTTCAGATTTGTGCAATTAATGAATCTTGATAATTTCTTA	1388		
Qy	1320	TGCAGATTGCTCAAAACAGCTTTATATTAAGCACAAATTAAGCTAG	1362		
Db	1389	TGCAGATTGCTCAAAACAGCTTTATATTAAGCACAAATTAAGCTAG	1431		
RESULT 7					
LOCUS	AX780232	2505 bp	DNA	linear	PAT 14-JUL-2003
DEFINITION	Sequence 2389 from Patent WO03039443.				
ACCESSION	AX780232				
VERSION	AX780232.1	GI:32697226			
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	1				
AUTHORS	Haerlach, T., Schoch, C., Kern, W., Kohlmann, A., Schnittger, S., Dugas, M., Eils, R., Biers, B. and Mergenthaler, S.				
TITLE	Novel genetic markers for leukemias				
JOURNAL	Patent: WO 03039443-A 2389 15-MAY-2003; Deutsches Krebsforschungszentrum (DE); Ludwig-Maximilian-Universitaet Muenchen (DE); Haerlach, Torsten, PD Dr. Dr. (DE); Schoch, Claudia (DE); Kern, Wolfgang (DE)				
FEATURES	Location/Qualifiers				
source	1..2505				
ORIGIN	/organism="Homo sapiens"				
	/mol_type="unassigned DNA"				
	/db_xref="taxon:9606"				

[illegible]

Db 1610 TGATCCTCGTGATTATAATTATTGGATATGTTGCAGTATTACTTGAATCTGCAGAGGC 1669

QY 1080 GAATCTAAAGGAGAGATCCATCTGAGCTGGAGTATATCCTGACCAGACCTAGACAT 1139

Db 1670 GAATCTAAAGGAGAGATCCATCTGAGCTGGAGTATATCCTGACCAGACCTAGACAT 1729

QY 1140 TGAAGATTGACGCCGGAAGTTTATATGATTTAGCTAAACAATTTACAATCCTAGACAG 1199

Db 1730 TGAAGATTGACGCCGGAAGTTTATATGATTTAGCTAAACAATTTACAATCCTAGACAG 1789

QY 1200 TAAGCAGTTTATAAATACTACAATTACTTTCTTTGTGAGTTATGACAGCAGTGAACATG 1259

Db 1790 TAAGCAGTTTATAAATACTACAATTACTTTCTTTGTGAGTTATGACAGCAGTGAACATG 1849

QY 1260 TGATAAGCATGTAAAGCCTTTGAGATTGTGCAATTATGAATCTTGATAATATTCCCTA 1319

Db 1850 TGATAAGCATGTAAAGCCTTTGAGATTGTGCAATTATGAATCTTGATAATATTCCCTA 1909

QY 1320 TGCAGATTGCTCAAAACAGCTTTATATTAAGCACAACTTACTAG 1362

Db 1910 TGCAGATTGCTCAAAACAGCTTTATATTAAGCACAACTTACTAG 1952

RESULT 8  
CQ414095 2049 bp DNA linear PAT 23-JAN-2004

LOCUS CQ414095 Sequence 21166 from Patent WO0170979.

DEFINITION CQ414095

ACCESSION CQ414095

VERSION CQ414095.1 GI:41321876

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

REFERENCE 1 Lee,J. and Lillie,J. Genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer Patent: WO 0170979-A 21166 27-SEP-2001; Millennium Pharmaceuticals, Inc. (US)

FEATURES source 1. 2049 /organism="Homo sapiens" /mol\_type="unassigned DNA" /db\_xref="taxon:9606"

ORIGIN

Query Match 76.0%; Score 1035.4; DB 6; Length 2049;  
Best Local Similarity 99.9%; Pred. No. 1.5e-246;  
Matches 1036; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 326 GGGATAGCCCACTCATGTTCTGTACCTGTAACCTCTCAACAGACACTGTTATAATGTGA 385

Db 210 GGGATAGCCCACTCATGTTCTGTACCTGTAACCTCTCAACAGACACTGTTATAATGTGA 269

QY 386 TCACCTAATGACAACAACCATCCAGAGTCTCTTCCAAATCTCCAGGTTTCCCTGCGC 445

Db 270 TCACCTAATGACAACAACCATCCAGAGTCTCTTCCAAATCTCCAGGTTTCCCTGCGC 329

QY 446 TGGGTAAATCATGACTATTGGCCACAGATCAACTGTCTGTAGTCCACGATAAGTGTACA 505

Db 330 TGGGTAAATCATGACTATTGGCCACAGATCAACTGTCTGTAGTCCACGATAAGTGTACA 389

QY 506 ATGCAGTAGCAAACTCTTGAAAACCATGGCTAGATGAAGAAGCTATTAGTACTTTAAGGA 565

Db 390 ATGCAGTAGCAAACTCTTGAAAACCATGGCTAGATGAAGAAGCTATTAGTACTTTAAGGA 449

QY 566 AAGGTGTTTATTATTCACAGAAAGTTAACAATAATCCAAACCTTAGATCATCAGTCTAA 625

Db 450 AAGGTGTTTATTATTCACAGAAAGTTAACAATAATCCAAACCTTAGATCATCAGTCTAA 509

QY 626 ACACAAACTGTACTAGGCCCAAAATTAATGACACTGAACCAAGACTGACCCAGCCAACC 685

Db 510 ACACAACTTGTACTACGCCCAAAATATAATGACACTGAACAAAGACTGACCCAGCCAAC 569

QY 686 AGTTGAATGGCTAGAAAAGTACATTGAACAACTCTCAGCAGAAATAAGAGAGGTGTATA 745

Db 570 AGTTGAATGGCTAGAAAAGTACATTGAACAACTCTCAGCAGAAATAAGAGAGGTGTATA 629

QY 746 TCATAGCACATGTTCCAGTGGGGTATCTGCCATCTTCAGAGAATCAACAGCAATGAGAG 805

Db 630 TCATAGCACATGTTCCAGTGGGGTATCTGCCATCTTCAGAGAATCAACAGCAATGAGAG 689

QY 806 AATTAATAATGAGAAATTGATAGATATTTTCCAAAATAACAGTGATGTCATTGCGAGAC 865

Db 690 AATTAATAATGAGAAATTGATAGATATTTTCCAAAATAACAGTGATGTCATTGCGAGAC 749

QY 866 AATTTATGACACACTCAGACAGACAGCAATTATGTTCTTTTCAGATTAATAAAGAGAGTC 925

Db 750 AATTTATGACACACTCAGACAGACAGCAATTATGTTCTTTTCAGATTAATAAAGAGAGTC 809

QY 926 CAGTAAATTCCTTTGTTGTGGCTCCTGCTGTTACACCAAGTGAAGAGTGTAGAAAAAC 985

Db 810 CAGTAAATTCCTTTGTTGTGGCTCCTGCTGTTACACCAAGTGAAGAGTGTAGAAAAAC 869

QY 986 AGACCAACAATCCTGATAGACTGTTTCAGTATGATCCTCGTATTATAAATTATG 1045

Db 870 AGACCAACAATCCTGATAGACTGTTTCAGTATGATCCTCGTATTATAAATTATG 929

QY 1046 ATAATGTCAGTATTACTTGAATCTGACAGAGGCGAATCTAAAGGAGAGTCCATCTGA 1105

Db 930 ATAATGTCAGTATTACTTGAATCTGACAGAGGCGAATCTAAAGGAGAGTCCATCTGA 989

QY 1106 AGCTGAGTATATCCTGACCCAGACCTAGACATTTGAAGATTTGACGCCGAAGTTAT 1165

Db 990 AGCTGAGTATATCCTGACCCAGACCTAGACATTTGAAGATTTGACGCCGAAGTTAT 1049

QY 1166 ATGATTAAGCTAAACAATTACAAATCCTAGACAGTGAAGAGTTTATAAATACTACAATT 1225

Db 1050 ATGATTAAGCTAAACAATTACAAATCCTAGACAGTGAAGAGTTTATAAATACTACAATT 1109

QY 1226 ACTTCTTTGTGAGTTATGACAGCAGTGAACATGTGATGAAGCATGTAAAGCCTTCAGA 1285

Db 1110 ACTTCTTTGTGAGTTATGACAGCAGTGAACATGTGATGAAGCATGTAAAGCCTTCAGA 1169

QY 1286 TTTGTCAATTATGAATCTTGATTAATATTTTCTATGACAGATTGCTCAACAGCCTTATA 1345

Db 1170 TTTGTCAATTATGAATCTTGATTAATATTTTCTATGACAGATTGCTCAACAGCCTTATA 1229

QY 1346 TAAAGCAATTTACTAG 1362

Db 1230 TAAAGCAATTTACTAG 1246

RESULT 9  
AX305693 1758 bp DNA linear PAT 11-DEC-2001

LOCUS AX305693 Sequence 444 from Patent WO0188188.

DEFINITION AX305693

ACCESSION AX305693

VERSION AX305693.1 GI:17645124

KEYWORDS Mus musculus (house mouse)

SOURCE Mus musculus

ORGANISM Mus musculus

REFERENCE 1 Ishikawa,K., Asai,S., Takahashi,Y., Nagata,T. and Ishii,Y. Method for examining ischemic conditions Patent: WO 0188188-A 444 22-NOV-2001; School Juridical Person Nihon University (JP)

FEATURES source 1. 1758 /organism="Mus musculus" /mol\_type="unassigned DNA" /db\_xref="taxon:10090"

ORIGIN











```

KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE     1
AUTHORS       Kaplow, J., Haws, T., Rosier, M. and Denefle, P.
TITLE         Nuclear factor Kb inducing factor
JOURNAL       Patent: WO 0174900-A 4 11-OCT-2001;
              Aventis Pharmaceuticals Products Inc. (US)
FEATURES      location/Qualifiers
              1..1095
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

```

## ORIGIN

Query Match	59.9%;	Score 816.4;	DB 6;	Length 1095;
Best Local Similarity	80.3%;	Pred. No. 4.5e-192;		
Matches 1094; Conservative	0;	Mismatches 1;	Indels 267;	Gaps 1;

[illegible]

QY	781	TCACAGAACATCACAGCAATGAGAAATACTATATATGAGAAATTGATAGATATTTTCAA	840
Db	514	TCACAGAACATCACAGCAATGAGAAATACTATATGAGAAATTGATAGATATTTTCAA	573
QY	841	AAATACAGTATGTCATTGCAAGACAATTTTATGCAACACTCACAGACAGACATTAATG	900
Db	574	AAATACAGTATGTCATTGCAAGACAATTTTATGCAACACTCACAGACAGACATTAATG	633
QY	901	GTTCTTTCAGATTAATAAAGGAAGTCCAGTAATCTTTGTTGTGGCTCCTGCTGTACA	960
Db	634	GTTCTTTCAGATTAATAAAGGAAGTCCAGTAATCTTTGTTGTGGCTCCTGCTGTACA	693
QY	961	CCAGTGAAGAGTGTTTAGAAAAACAGACCAACAATCCTGTATCAGACTGTTCACTAT	1020
Db	694	CCAGTGAAGAGTGTTTAGAAAAACAGACCAACAATCCTGTATCAGACTGTTCACTAT	753
QY	1021	GATCCTCGTATTTAAATTATTTGGATATGTTGCAATTACTTGAATCTGACAGGCG	1080
Db	754	GATCCTCGTATTTAAATTATTTGGATATGTTGCAATTACTTGAATCTGACAGGCG	813
QY	1081	AATCTAAAGGAGAGTCCATCTGGAAGCTGAGTATATCCTGACCCAGACCTACGACATT	1140
Db	814	AATCTAAAGGAGAGTCCATCTGGAAGCTGAGTATATCCTGACCCAGACCTACGACATT	873
QY	1141	GAAGATTTGCAGCCGGAAAGTTTATATGATTAGCTAAACAATTACAAATCCTAGACAGT	1200
Db	874	GAAGATTTGCAGCCGGAAAGTTTATATGATTAGCTAAACAATTACAAATCCTAGACAGT	933
QY	1201	AAGCAGTTTATATAAATACTACAATTACTCTTTGTGAGTTATGACAGCAGTGTACATGT	1260
Db	934	AAGCAGTTTATATAAATACTACAATTACTCTTTGTGAGTTATGACAGCAGTGTACATGT	993
QY	1261	GATAAGACATGTAAGCCTTTCAGATTGTGCAATTATGAATCTTGATAATATTTCTTAT	1320
Db	994	GATAAGACATGTAAGCCTTTCAGATTGTGCAATTATGAATCTTGATAATATTTCTTAT	1053
QY	1321	GCAGATTGCCCTCAAAACAGCTTATATATAAGCACAAATTAATACTAG 1362	
Db	1054	GCAGATTGCCCTCAAAACAGCTTATATATAAGCACAAATTAATACTAG 1095	

## RESULT 13

LOCUS	CQ717782	893 bp	DNA	linear	PAT 03-FEB-2004
DEFINITION	Sequence 3716 from Patent WO02068579.				

ACCESSION	CQ717782
VERSION	CQ717782.1
	GI:42278639

KEYWORDS	.
SOURCE	Homo sapiens (human)

ORGANISM    Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE	AUTHORS	TITLE
1	Venter, C.J., Adams, M.C., Li, P.W. and Myers, E.W.	Kits, such as nucleic acid arrays, comprising a majority of

humanexons or transcripts, for detecting expression and other uses thereof  
Patent: WO 02068579-A 3716 06-SEP-2002;  
JOURNAL

PE Corporation (NY) (US)	Location/Qualifiers
source	1. .893

```
/organism="Homo sapiens"  
/mol_type="unassigned DNA"  
/db_xref="taxon:9606"
```

ORIGIN

Query Match	52.7%;	Score 717.4;	DB 6;	Length 893;
Best Local Similarity	99.9%;	Pred. No. 1.9e-167;		
Matches 718; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

QY 326 GGGATAGCCCCACCTCATGTTCCGTACTGAACCTCTCAACAGACACTGTTATAAATGTGA 385  
|||||  
Db 175 GGGATAGCCCCACCTCATGTTCCGTACTGAACCTCTCAACAGACACTGTTATAAATGTGA 234

QY 386 TCACATATATGACAAACCAACCATCCAGAGTCTCTTCCAAATCTCCAGGTTTCCCTGCGC 445  
Db 235 TCACTAATATGACAAACCAACCATCCAGAGTCTCTTCCAAATCTCCAGGTTTCCCTGCGC 294  
QY 446 TGGGTAATCATGACTATTGGCCACAGATCACTGTCTGTAGTCACCAAGTAAGTGACA 505  
Db 295 TGGGTAATCATGACTATTGGCCACAGATCACTGTCTGTAGTCACCAAGTAAGTGACA 354  
QY 506 ATGACAGTACAACTCTGGAACCATGGCTAGTGAAGAAGCTATTAGTACTTTAAGGA 565  
Db 355 ATGACAGTACAACTCTGGAACCATGGCTAGTGAAGAAGCTATTAGTACTTTAAGGA 414  
QY 566 AAGGTGTTTATTACAGAAAGTTACAACCTTAACCTTAGATCATCAGTCTAA 625  
Db 415 AAGGTGTTTATTACAGAAAGTTACAACCTTAACCTTAGATCATCAGTCTAA 474  
QY 626 ACACAACTTGTACTACGGCCCAATATATGACATGAACAAGACTGACCCCAACC 685  
Db 475 ACACAACTTGTACTACGGCCCAATATATGACATGAACAAGACTGACCCCAACC 534  
QY 686 AGTTGAATGGCTAGAAAGTACATTGAACAATCTCAGCAGAAATGAAGAGGTGTATA 745  
Db 535 AGTTGAATGGCTAGAAAGTACATTGAACAATCTCAGCAGAAATGAAGAGGTGTATA 594  
QY 746 TCATAGCACATGTTCCAGTGGGGTATCTGCCATCTTCAAGACATCAGCAATGAGAG 805  
Db 595 TCATAGCACATGTTCCAGTGGGGTATCTGCCATCTTCAAGACATCAGCAATGAGAG 654  
QY 806 AATACATATATGAGAAATGTAGATATTTTCAAAATACAGTATGATGATTCAGAGAC 865  
Db 655 AATACATATATGAGAAATGTAGATATTTTCAAAATACAGTATGATGATTCAGAGAC 714  
QY 866 AATTATGACACACTCAGAGACAGCATATGTTCTTTCAGATTAATAAAGAAAGTC 925  
Db 715 AATTATGACACACTCAGAGACAGCATATGTTCTTTCAGATTAATAAAGAAAGTC 774  
QY 926 CAGTAAATCTTTGTTGTGGCTCCTGCTGTATACCAAGTGAAGAGTGTTTAGAAAAAC 985  
Db 775 CAGTAAATCTTTGTTGTGGCTCCTGCTGTATACCAAGTGAAGAGTGTTTAGAAAAAC 834  
QY 986 AGACCAACAATCTGCTATCAGACTGTTTCAGTATGATCCTGCTGATTAATAATTATTG 1044  
Db 835 AGACCAACAATCTGCTATCAGACTGTTTCAGTATGATCCTGCTGATTAATAATTATTG 893

RESULT 14  
BD21252 728 bp DNA linear PAT 17-JUL-2003  
LOCUS BD21252 Human gene and gene expression product V.  
DEFINITION BD21252  
ACCESSION BD21252.1 GI:33031022  
VERSION JP 2002534055-A/2365.  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 728)  
AUTHORS Williams,L.T., Escobedo,J., Innis,M.A., Garcia,P.D., Klinger,J.S.,  
Reinhard,C., Giese,K., Randazzo,F., Kennedy,G.C., Pot,D.,  
Kassam,A., Lamson,G., Drmanac,R., Crkvenjakov,R., Dickson,M.,  
Drmanac,S., Labat,I., Leshkowitz,D., Kita,D., Garcia,V., Jones,L.W.  
and Crain,B.S.  
Human gene and gene expression product V  
Patent: JP 2002534055-A 2365 15-OCT-2002;  
TITLE CHIRON CORP, HYSEQ INC  
JOURNAL OS Homo sapiens (human)  
PN JP 2002534055-A/2365  
PD 15-OCT-2002  
PF 13-MAY-1999 JP 2000548466  
PR 14-MAY-1998 US 60/085426,15-MAY-1998 US 60/085537 PR  
15-MAY-1998 US 60/085696,21-OCT-1998 US 60/105234 PR  
27-OCT-1998 US 60/105877

PI LOUIS T WILLIAMS,JAIME ESCOBEDO,MICHAEL A INNIS,PABLO PI  
DOMINGUEZ GARCIA,  
PI JULIE SUDUTH KLINGER,CHRISTOPH REINHARD,KLAUSE GIESE,FILIPPO  
PI RANDAZZO,  
PI GIULIA C KENNEDY,DAVID POT,ALTAI KASSAM,GEORGE LAMSON,RADOJE  
PI DRMANAC,  
PI RADOJIR CRKVENJAKOV,MARK DICKSON,SNEZANA DRMANAC,IVAN LABAT,  
PI DENA LESHKOWITZ,DAVID KITA,VERONICA GARCIA,LEE WILLIAM JONES,  
PI BIRGIT STACHE CRAIN  
PC C12N5/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21 PC  
,C12N5/00,C12Q1/68,  
PC C12N15/00,C12N5/00  
CC n = A,T,C or G  
FH Key Location/Qualifiers  
FT misc feature (1)..(728).  
FEATURES  
source 1..728  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
ORIGIN  
Query Match 51.4%; Score 700.2; DB 6; Length 728;  
Best Local Similarity 98.7%; Pred. No. 3.5e-163;  
Matches 705; Conservative 0; Mismatches 9; Indels 0; Gaps 0;  
QY 315 GATATGACAGGGGATAGCCCACTCATGTTCTCTGTACTCTGAACCTCTCAACAGACACTGT 374  
Db 15 GATTCGGACGAGGATAGCCCACTCATGTTCTCTGTACTCTGAACCTCTCAACAGACACTGT 74  
QY 375 TATAAATGTGATCACTAATATGACAAACCATCCAGAGTCTCTTCCAAATCTCCAGGT 434  
Db 75 TATAAATGTGATCACTAATATGACAAACCATCCAGAGTCTCTTCCAAATCTCCAGGT 134  
QY 435 TTTCCCTGCGCTGGGTAAATCATGACTATTGGCCACAGAGTCAACTGTCTGTAGTCAACAG 494  
Db 135 TTTCCCTGCGCTGGGTAAATCATGACTATTGGCCACAGAGTCAACTGTCTGTAGTCAACAG 194  
QY 495 TAAAGTGTACAATGACAGTAAACCTCTGGAACCATGGCTGATGAAGAAGCTATTAG 554  
Db 195 TAAAGTGTACAATGACAGTAAACCTCTGGAACCATGGCTGATGAAGAAGCTATTAG 254  
QY 555 TACTTTAAGGAAAGGTGTTTATTTATTCACAGAAAGTTACAATCACTAATCCAACTTAGAT 614  
Db 255 TACTTTAAGGAAAGGTGTTTATTTATTCACAGAAAGTTACAATCACTAATCCAACTTAGAT 314  
QY 615 CATCAGTCTTAAACAACTTGTACTACGGCCCAATATATATGACACTGAACAAGACTGA 674  
Db 315 CATCAGTCTTAAACAACTTGTACTACGGCCCAATATATATGACACTGAACAAGACTGA 374  
QY 675 CCCAGCCAACTGTTGAATGGCTAGAAAGTACATTTGAACAACCTCTCAGCAATTAAGA 734  
Db 375 CCCAGCCAACTGTTGAATGGCTAGAAAGTACATTTGAACAACCTCTCAGCAATTAAGA 434  
QY 735 GAAGTGTATATCATAGCACATGTTCCAGTGGGGTATCTGCCATCTTCAAGAACATCAC 794  
Db 435 GAAGTGTATATCATAGCACATGTTCCAGTGGGGTATCTGCCATCTTCAAGAACATCAC 494  
QY 795 AGCAATGAGAGAAATCTATATGAGAAATGTAGATATTTTCAAAATACAGTATGT 854  
Db 495 AGCAATGAGAGAAATCTATATGAGAAATGTAGATATTTTCAAAATACAGTATGT 554  
QY 855 CATTGACAGCAATTTATGACACACTCAGAGACAGACATTAATGTTCTTTCAGATTA 914  
Db 555 CATTGACAGCAATTTATGACACACTCAGAGACAGACATTAATGTTCTTTCAGATTA 614  
QY 915 AAAAGGAGTCCAGTAAATCTTTGTTGTGGCTCCTGCTGTTAACAGTGAAGAGTGT 974  
Db 615 AAAAGGAGTCCAGTAAATCTTTGTTGTGGCTCCTGCTGTTAACAGTGAAGAGTGT 674  
QY 975 TTTAGAAAAACAGACCAACATCTGCTATCAGACTGTTTCAGTATGATCCTCG 1028  
Db 675 TTTAGAAAAACAGACCAACATCTGCTATCAGACTGTTTCAGTATGATCCTCG 728





Wed Apr 6 15:08:45 2005

us-09-823-119b-3.rge

Page 15

Search completed: April 5, 2005, 09:16:57  
Job time : 5850 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - nucleic search, using frame\_plus\_p2n model

Run on: April 5, 2005, 10:08:58 ; Search time 628 Seconds  
(without alignments)  
4270.132 Million cell updates/sec

Title: US-09-823-119B-1  
Perfect score: 2427  
Sequence: 1 MALVRAIVCCLLTAMHCRSG.....NLDNISYADCLKQLYIKHNY 453

Scoring table: BLOSUM62  
Xgapop 10.0 , Xgapext 0.5  
Ygapop 10.0 , Ygapext 0.5  
Fgapop 6.0 , Fgapext 7.0  
Delop 6.0 , Delext 7.0

Searched: 4390206 segs, 2959870667 residues

Total number of hits satisfying chosen parameters: 8780412

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Command line parameters:

MODEL=frame+p2n.model -DEV=xlp  
-Q=/cgn2\_1/USPTO\_spool\_p/US09823119/runat\_05042005\_084015\_6991/app\_query.fasta\_1.647  
-DB=N\_Geneseq\_16Dec04 -QFMT=fastap -SUFFIX=ring -MINMATCH=0.1 -LOOPEXT=0  
-LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi  
-LIST=45 -DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15  
-MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000  
-USER=US09823119 @CGN 1 1 708 @runat\_05042005\_084015\_6991 -NCPU=6 -ICPU=3  
-NO\_MMAPP -LARGEQUERY -NEG\_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG  
-DEV\_TIMEOUT=120 -WARN\_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6  
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : N\_Geneseq\_16Dec04:\*

- 1: geneseqn1980s:\*
- 2: geneseqn1990s:\*
- 3: geneseqn2000s:\*
- 4: geneseqn2001as:\*
- 5: geneseqn2001bs:\*
- 6: geneseqn2002as:\*
- 7: geneseqn2002bs:\*
- 8: geneseqn2003as:\*
- 9: geneseqn2003bs:\*
- 10: geneseqn2003cs:\*
- 11: geneseqn2003ds:\*
- 12: geneseqn2004as:\*
- 13: geneseqn2004bs:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	2427	100.0	1362	4	AAD21343	Aad21343 Human nuc
2	2422	99.8	1763	10	ADH61155	Adh61155 Human hyd
3	2422	99.8	1764	4	AAC60227	Aac60227 Human hyd
4	2422	99.8	1764	9	ADA10929	Ada10929 Human CDN
5	2422	99.8	1764	10	ADB90834	Adb90834 Human CDN

6	2422	99.8	1768	12	ADJ45508	Adj45508 cDNA enco
7	2413	99.4	1783	6	AAS62765	Aas62765 cDNA sequ
8	2409	99.3	1746	6	AAS94849	Aas94849 Human DNA
9	2355	97.0	2505	10	ADF81833	Adf81833 Leukaemia
10	2223	91.6	1873	4	AAI61110	Aai61110 Human pol
11	2223	91.6	1874	4	AAI53324	Aai59324 Human pol
12	1962.5	80.9	2049	5	ADL62954	Adl62954 Human ova
13	1953.5	80.5	1758	6	AB199482	Abi99482 Mouse isc
14	1903.5	78.4	1095	4	AAD21344	Aad21344 Human nuc
15	1209	49.8	728	3	AAA02374	Aaa02374 Human col
16	1162	47.9	733	3	AAA02333	Aaa02333 Human col
17	1101	45.4	939	5	AAH20423	Aah20423 Human sph
18	1004	41.4	559	6	ABN60406	Abn60406 Human can
19	986.5	40.6	778	3	AAA02346	Aaa02346 Human col
20	956	39.4	773	3	AAA02332	Aaa02332 Human col
21	932	38.4	540	6	ABN60975	Abn60975 Human can
22	930	38.3	863	6	ABL62490	Ab162490 Colon ade
23	930	38.3	863	6	ABL61985	Ab161985 Colon ade
24	930	38.3	863	6	ABK84743	Abk84743 Human CDN
25	930	38.3	863	8	ACA89936	Aca89936 Gene diff
26	930	38.3	863	10	ADH28998	Adh28998 Human chr
27	930	38.3	863	13	ADP24656	Adp24656 PRO polyP
28	921	37.9	1489	4	AAH99916	Aah99916 Nucleotid
29	921	37.9	1814	4	AAI59259	Aai59259 Human pol
30	921	37.9	1816	4	AAI61045	Aai61045 Human pol
31	917	37.8	1610	6	ABL68027	Ab168027 Ovary can
32	917	37.8	1610	6	ABL64782	Ab164782 Lung can
33	878	36.2	610	10	ADB90860	Adb90860 Human hyd
34	878	36.2	610	10	ADH61181	Adh61181 Human hyd
35	598.5	24.7	1902	4	ABL13819	Ab113819 Drosophil
36	543	22.4	317	10	ADB90862	Adb90862 Human hyd
37	543	22.4	317	10	ADH61183	Adh61183 Human hyd
38	519	21.4	300	3	AAA00750	Aaa00750 Human col
39	514.5	21.2	3264	4	ABL06061	Ab106061 Drosophil
40	486.5	20.0	1879	6	ABL59530	Ab159530 Human sph
41	486.5	20.0	2344	2	AAQ33394	Aaq33394 R496L ASM
42	486.5	20.0	2344	2	AAT95066	Aat95066 cDNA enco
43	486.5	20.0	2344	9	ACD28698	Acd28698 cDNA enco
44	486.5	20.0	2347	2	AAQ33390	Aaq33390 ASM cDNA,
45	486.5	20.0	2347	2	AAT95067	Aat95067 cDNA enco

ALIGNMENTS

RESULT 1	
AAD21343	
ID	AAD21343 standard; cDNA; 1362 BP.
AC	AAD21343;
XX	
DT	28-JAN-2002 (first entry)
XX	
DE	Human nuclear factor kappaB-inducing factor (NFIF) -14b cDNA.
KW	Human; NFkappaB; nuclear factor kappaB inducing factor; NFIF-14b;
KW	NFIF-7a; immune response; inflammatory response; atherosclerosis;
KW	rheumatoid arthritis; NSAID-induced gastropathy; scrapie; sepsis;
KW	neurodegenerative disease; autoimmune disease; antisense therapy;
KW	renal disease; restenosis; brain injury; viral disease; apoptosis;
KW	Alzheimer's disease; pleiotropic cytokine; gene therapy; asthma;
KW	Crohn's disease; ss.
XX	
OS	Homo sapiens.
XX	
FH	Key
FT	CDS
FT	1..1362
FT	/*tag= a
XX	/product= "Human NFIF-14b protein"
PN	W0200174900-A2.
XX	
PD	11-OCT-2001.
XX	



02-APR-2001; 2001WO-US010719.  
31-MAR-2000; 2000US-0193905P.  
26-JUL-2000; 2000GB-00018307.  
(AVET ) AVENTIS PHARM PROD INC.  
Kaplow J, Haws T, Rosier M, Deneffe P;  
WPI; 2001-662967/76.  
P-PSDB; AAEI3018.  
Novel isolated nuclear factor kappaB-inducing factor polypeptides (NFIF-7a, NFIF-14b), useful for increasing NFkappaB induction in patient, and for manufacturing medicaments for treating or preventing atherosclerosis.  
Claim 1; Fig 3; 87pp; English.  
The invention relates to nuclear factor kappaB (NFkappaB) inducing factor NFIF-14b, NFIF-7a (splice variant of NFIF14b) polypeptides and polynucleotides. NFIF-14b and NFIF-7a sequences are useful for inducing NFkappaB in vivo for increasing the activity of NFkappaB-regulated pathways including immune responses. Compositions comprising NFIF sequences are useful for treating or preventing NFkappaB-regulated inflammatory response such as rheumatoid arthritis, atherosclerosis, autoimmune diseases, viral diseases, NSAID-induced gastropathy, neurodegenerative diseases, scrapie, sepsis, apoptosis, Crohn's disease, renal disease, restenosis, brain injury/inflammation, Alzheimer's disease, asthma and improperly regulated expression of pleiotropic cytokines. They are also useful for inhibiting or lowering the expression of NFIF genes or polypeptides, respectively and thus for inhibiting induction of NFkappaB and consequently inhibiting or preventing NFkappaB-regulated immune responses that result in atherosclerosis and other diseases. Polynucleotides of the invention are useful in gene therapy and antisense therapy. The present sequence is human NFIF-14b cDNA

Alignment Scores:	
Pred. No.:	2.66e-224
Score:	2427.00
Percent Similarity:	100.00%
Best Local Similarity:	100.00%
Query Match:	100.00%
DB:	4
Length:	1362
Matches:	453
Conservative:	0
Mismatches:	0
Indels:	0
Gaps:	0

US-09-823-119B-1 (1-453) x AAD21343 (1-1362)

[illegible]

Db	361	TCACAGACACTGTTATAATGTGATCACTAATAATGACAACACCACCATCCAGAGTCTCTT	420
QY	141	ProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrTrpProGlnAspGlnLeu	160
Db	421	CCAAATCTCCAGGTTTCCCTCGCGCTGGGTATATCATGACTATTGGCCACAGATCAACTG	480
QY	161	SerValValThrSerLysValTyrAsnAlaValAlaAsnLeuTrpLysProTrpLeuAsp	180
Db	481	TCTGTAGTCACCAGTAAGTGTACAATGCAGTAGCAAACTCTTGAAAACCATGGCTAGAT	540
QY	181	GluGluAlaIleSerThrLeuArgLysGlyPheTyrSerGlnLysValThrThrAsn	200
Db	541	GAAGAAGCTATTAGTACTTTAAGGAAAGGTGGTTTATTTCACAGAAAGTTACAACTAAT	600
QY	201	ProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrTyrGlyProAsnIleMetThr	220
Db	601	CCAAACCTTAGATCATCAGTCTAAACACAAACTTGTACTACGCCCAATATTAATGACA	660
QY	221	LeuAsnLysThrAspProAlaAsnGlnPheGlnTrpLeuGlnSerThrLeuAsnSer	240
Db	661	CTGAACAGACTGACCCAGCCAAACCAGTTTGAAATGGCTAGAAAGTACATTGAACAACTCT	720
QY	241	GlnGlnAsnLysGlnLysValTyrIleIleAlaHisValProValGlyTyrLeuProSer	260
Db	721	CAGCAGAATAAGAGAGAGTGATATATCATAGCATGTTCAGTGGGGTATCTGCCATCT	780
QY	261	SerGlnAsnIleThrAlaMetArgGluTyrTyrAsnGlnLysLeuIleAspIlePheGln	280
Db	781	TCACAGAACATCACAGCAATGAGAAATACTATTAATGAGAAATTGATAGATATTTTCAA	840
QY	281	LysTyrSerAspValIleAlaGlyGlnPheTyrGlyHisThrHisArgAspSerIleMet	300
Db	841	AAATACAGTATGTCAATTGCAGACAAATTTTATGACACACTCACAGAGACAGCATATG	900
QY	301	ValLeuSerAspLysLysGlySerProValAsnSerLeuPheValAlaProAlaValThr	320
Db	901	GTTCTTTCAGATAAAAGAAAGTCCAGTAAATCTTTGTTGTGCTCCTGCTGTTACA	960
QY	321	ProValLysSerValLeuGlnLysGlnThrAsnAsnProGlyIleArgLeuPheGlnTyr	340
Db	961	CCAGTGAAGAGTGTTTAGAAAAAACAGACCACACATCCTGGTATCAGACTGTTCAAGTAT	1020
QY	341	AspProArgAspTyrLysLeuLeuAspMetLeuGlnTyrTyrLeuAsnLeuThrGluAla	360
Db	1021	GATCCTCGTATTAATAATTATTTGATATGTTCAGTATTACTTGAAATCTGCACAGGCG	1080
QY	361	AsnLeuLysGlyGlnSerIleTrpLysLeuGlnTyrIleLeuThrGlnThrTyrAspIle	380
Db	1081	AATCTAAAGGAGAGTCCATCTGGAAGCTGGAGTATATCTGACCAGACCTTAGACATT	1140
QY	381	GluAspLeuGlnProGlnSerLeuTyrGlyLeuAlaLysGlnPheThrIleLeuAspSer	400
Db	1141	GAAGATTTGCAGCCGGAAGTTTATATGATTAAGTAAACAATTACAAATCTTAGACAGT	1200
QY	401	LysGlnPheIleLysTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCys	420
Db	1201	AAGCAGTTTATAAATACTACAATTACTTCTTGAGAGTTATGACAGCAGTGAACATGT	1260
QY	421	AspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTyr	440
Db	1261	GATTAAGACATGTAAAGCCTTTCAGATTGTGCATTATGAATCTTGATAATATTCTCTAT	1320
QY	441	AlaAspCysLeuLysGlnLeuTyrIleLysHisAsnTyr 453	
Db	1321	GCAGATTGCCTCAACAGCTTTATATATAAGACAAATTAC 1359	
RESULT 2			
ADH61155			
ID	ADH61155	standard; cDNA; 1763 BP.	
XX	AC	ADH61155;	
XX	XX		

DT 25-MAR-2004 (first entry)  
XX Human hydrolase-like molecule (HHLM) 5 cDNA #1.  
DE Human; hydrolase-like molecule; HHLM; cancer; arteriosclerosis;  
KW cyostatic; therapy; gene; ss.  
XX Homo sapiens.  
OS  
FH Key Location/Qualifiers  
FT CDS 68..1429  
FT /\*tag= a  
FT /product= "Human hydrolase-like molecule (HHLM) protein"  
XX  
XX US2003148363-A1.  
XX PD 07-AUG-2003.  
XX PF 05-FEB-2003; 2003US-00359499.  
XX PR 06-FEB-1998; 98US-00013881.  
PR 07-JUL-2000; 2000US-00612473.  
XX PA (INCY-) INCYTE GENOMICS INC.  
XX PI Bandman O, Lal P, Hillman JL, Corley NC, Guegler KJ, Shah P;  
XX WPI; 2003-897560/82.  
DR P-PSDB; ADH61147.  
XX  
PT New human hydrolase-like molecules (HHLM), useful for preparing a  
PT composition for diagnosing, treating or preventing a disease or condition  
PT associated with expression of HHLM e.g. cancer or arteriosclerosis.  
XX  
PS Claim 5; SEQ ID NO 13; 60bp; English.  
XX  
CC The invention relates to human hydrolase-like molecules (HHLM) and their  
CC corresponding nucleic acid sequences. The sequences of the invention are  
CC useful for preparing a composition for diagnosing or treating a disease  
CC or condition associated with decreased expression or over expression of  
CC HHLM e.g., cancer or arteriosclerosis. The present sequence is human  
CC hydrolase-like molecule (HHLM) cDNA.  
XX  
SQ Sequence 1763 BP; 537 A; 356 C; 343 G; 527 T; 0 U; 0 Other;  
  
Alignment Scores:  
Pred. No.: 1.17e-223 Length: 1763  
Score: 2422.00 Matches: 452  
Percent Similarity: 99.78% Conservative: 0  
Best Local Similarity: 99.78% Mismatches: 1  
Query Match: 99.79% Indels: 0  
DB: 10 Gaps: 0  
  
US-09-823-119B-1 (1-453) x ADH61155 (1-1763)  
QY 1 MetAlaLeuValArgAlaLeuValCysCysLeuLeuThrAlaTrpHisCysArgSerGly 20  
DB 68 ATGGCGCTGGTGGCGCACTCGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCGGC 127  
QY 21 LeuGlyLeuProValAlaProAlaGlyGlyArgAsnProProProAlaIleGlyInPhe 40  
DB 128 CTGGGCTGCCCGTGGCGCCGCGAGCGGAGAAATCCTCCTCCGCGATAGACAGTTT 187  
QY 41 TrpHisValThrAspLeuHisLeuAspProThrTyrHisIleThrAspAspHisThrLys 60  
DB 188 TGGCATGTGACTGACTTACCTAGACCTTACCTACATCACAGATGACACACAAAA 247  
QY 61 ValCysAlaSerSerLysGlyAlaAsnAlaSerAsnProGlyProPheGlyAspValLeu 80  
DB 248 GTGTGTGCTTCATCTAAAGGTGCAAAATGCTCCAACTGGCCCTTTGGAGATGTTCTG 307  
QY 81 CysAspSerProTyrGlnLeuIleLeuSerAlaPheAspPheIleLysAsnSerGlyGln 100

DB 308 TGTGATTCCTCATATCACTTATTTTGTGACGATTGATTGATTATTAATAATCTGACAA 367  
QY 101 GluAlaSerPheMetIleTrpThrGlyAspSerProProHisValProValProGluLeu 120  
DB 368 GAAGCATCTTTCATGATATGACAGGGGATAGCCACCTCATGTTCTGTACTGAAGCTC 427  
QY 121 SerThrAspThrValIleAsnValIleThrAsnMetThrThrIleGlnSerLeuPhe 140  
DB 428 TCACAGACACTGTTATTAATGTGATCTAATATGACACACCACCATCCAGAGTCTCTT 487  
QY 141 ProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrTyrProGlnAspGlnLeu 160  
DB 488 CCAATCTCCAGGTTTCCCTGCGGTGGTAATCATGACTATTGGCCACAGATCAACTG 547  
QY 161 SerValValThrSerLysValTyrAsnAlaValAlaAsnLeuTrpLysProTrpLeuAsp 180  
DB 548 CCTGTAGTACACAGTAAAGTGTACAAATGACAGCAAACTTGGAACCATGGCTAGAT 607  
QY 181 GluGluAlaIleSerThrLeuArgLysGlyGlyPheTyrSerGlnLysValThrThrAsn 200  
DB 608 GAAGAAGCTATTAGTACTTTAAGAAAGGTGTTTATTATTCACAGAAAGTTACAACATA 667  
QY 201 ProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrTyrGlyProAsnIleMetThr 220  
DB 668 CCAACCTTAGATCATCATGCTTAACACAACTTGACTACGGCCCAATATATAGACA 727  
QY 221 LeuAsnLysThrAspProAlaAsnGlnPheGluTrpLeuGluSerThrLeuAsnAsnSer 240  
DB 728 CTGAACAAGACTGACCCAGCAACCACTTTGAATGGCTAGAAAGTACATTGAACAACACTCT 787  
QY 241 GlnGlnAsnLysGluLysValTyrIleIleAlaHisValProValGlyTyrLeuProSer 260  
DB 788 CAGCAGAATAGAGAAAGGTGTATATCATAGCACATGTTCCAGTGGGTATCTGCCATCT 847  
QY 261 SerGlnAsnIleThrAlaMetArgGluTyrTyrAsnGluLysLeuIleAspIlePheGln 280  
DB 848 TCACAGAACTCACAGCAATGAGAAATCTAATAGAGAAATGATATATTTTCAA 907  
QY 281 LysTyrSerAspValIleAlaGlyGlnPheTyrGlyHisThrHisArgAspSerIleMet 300  
DB 908 AATACAGTGTATCATTCGACAGCAATTTATGACACACTCACAGACAGACATTATG 967  
QY 301 ValLeuSerAspLysLysGlySerProValAsnSerLeuPheValAlaProAlaValThr 320  
DB 968 GTTCTTTCAATATAAAGGAAGTCCAGTAATTTCTTGTGTGGCTCCTGCTGTACA 1027  
QY 321 ProValLysSerValLeuGluLysGlnThrAsnAsnProGlyIleArgLeuPheGlnTyr 340  
DB 1028 CCAGTGAAGAGTGTTTAGAAAAACAGCAACAATCCTGGTATCAGACTGTTCAAGTAT 1087  
QY 341 AspProArgAspTyrLysLeuLeuAspMetLeuGlnTyrTyrLeuAsnLeuThrGluAla 360  
DB 1088 GATCCTCGTGAATTATAATTATGTGATGTGACAGTATTACTGAAATCTGACAGAGCG 1147  
QY 361 AsnLeuLysGlyGluSerIleTrpLysLeuGluTyrIleLeuThrGlnThrTyrAspIle 380  
DB 1148 AATCTAAAGGAGAGTCCATCTGGAAGCTGGAGTATATCCTGACCCAGACCTACGACATT 1207  
QY 381 GluAspLeuGlnProGluSerLeuTyrGlyLeuAlaLysGlnPheThrIleLeuAspSer 400  
DB 1208 GAAGATTTCGACCCGGAAGTTTATATGAGATTAGCTAACAATTTCATCCTAGACAGT 1267  
QY 401 LysGlnPheIleLysTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCys 420  
DB 1268 AAGCAGTTTATTAATACTACCAATTACTTCTTTGTGAGTTATGACAGAGTGAACATGT 1327  
QY 421 AspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTyr 440  
DB 1328 GATAAGACATGTAAAGCCTTCAGATTGTGCAATTATGAATCTTGATTAATTTCTCTAT 1387  
QY 441 AlaAspCysLeuLysGlnLeuTyrIleLysHisAsnTyr 453  
DB 1388 GCAGATTGCTCAAAACAGCTTATATTAAGCACAAATTAC 1426





[illegible]

Db	189	TGGCATGTGACTGACTTACACTTAGACCCTACTTACCACATCACAGATGACCACAAAA	248
Qy	61	ValCysAlaSerSerLySGlyAlaAsnAlaSerAsnProGlyProPheGlyAspValLeu	80
Db	249	GTGTGTGCTTCATCTAAAGGTGCAAAATGCTCCAAACCTGGCCCTTTTGAGATGTTCTG	308
Qy	81	CysAspSerProTyrGlnLeuIleLeuSerAlaPheAspPheIleLysAsnSerGlyGln	100
Db	309	TGTGATTCTCCATATCAACTTATTGTGTGAGCAATTTGATTTTATTAATAATCTGACAA	368
Qy	101	GluAlaSerPheMetIleTrpThrGlyAspSerProProHisValProValProGluLeu	120
Db	369	GAAGCATCTTTCATGATATGACAGAGGGATAGCCCACTCATGTCTCTGTACTGAACTC	428
Qy	121	SerThrAspThrValIleAsnValIleThrAsnMetThrThrTrileGlnSerLeuPhe	140
Db	429	TCAACAGACACCTGTATAAATGTGATCACTAAATATGACAACACCATCCAGAGTCTTT	488
Qy	141	ProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrTrpProGlnAspGlnLeu	160
Db	489	CCAAATCTCCAGGTTTTCCCTGCGTGGGTATCATGACTATTGGCCACAGATCAACTG	548
Qy	161	SerValValThrSerLySValTyrAsnAlaValAlaAsnLeuTrpLysProTrpLeuAsp	180
Db	549	CCTGTAGTCACCACTGAAAGTGTACAATGCAGTACCAAACTCTGGAACCATGCTAGAT	608
Qy	181	GluGluAlaIleSerThrLeuArgLySGlyGlyPheTyrSerGlnLysValThrAsn	200
Db	609	GAAAGAGCTATTAGTACTTTAAGGAAGGTGGTTTTTATTCACAGAAAGTTACAATAAT	668
Qy	201	ProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrTyrGlyProAsnIleMetThr	220
Db	669	CCAAACCTTAGGATCATCAGTCTAAACACAAACTTGTACTACGCCCAATATATGACA	728
Qy	221	LeuAsnLysThrAspProAlaAsnGlnPheGluTrpLeuGluSerThrLeuAsnSer	240
Db	729	CTGAACAAGACTGACCCAGCCAAACAGATTGGAATGGCTAGAAAGTACATTGAACAAC	788
Qy	241	GlnGlnAsnLySGlyLysValTyrIleIleAlaHisValProValGlyTyrLeuProSer	260
Db	789	CAGCAGAATAAGGAGAAAGGTATATCATAGCATGTCCAGTGGGATCTGCCACTCT	848
Qy	261	SerGlnAsnIleThrAlaMetArgGluTyrTyrAsnGluLysLeuIleAspIlePheGln	280
Db	849	TCACAGAACATCACAGCAATGAGAGATACTATATGAGAAATTGATAGATATTTTCCA	908
Qy	281	LysTyrSerAspValIleAlaGlyGlnPheTyrGlyHisThrHisArgAspSerIleMet	300
Db	909	AAATACAGTATGATTCATTGCAGACAAATTTATGACACACTCACAGAGACGATTATG	968
Qy	301	ValLeuSerAspLySlySGlySerProValAsnSerLeuPheValAlaProAlaValThr	320
Db	969	GTTCTTTCAGATAAAAAAGGAAGTCCAGTAAATCTTTGTTGTGGCTCCTGCTGTACA	1028
Qy	321	ProValLysSerValLeuGluLysGlnThrAsnAsnProGlyIleArgLeuPheGlnTyr	340
Db	1029	CCAGTGAAAGAGTGTTTAGAAAAACAGACCAACAATCTCTGTATCAGACTGTTCAGTAT	1088
Qy	341	AspProArgAspTyrLysLeuLeuAspMetLeuGlnTyrTyrLeuAsnLeuThrGluAla	360
Db	1089	GATCCTCGTATTAATAATTATTGGATATGTCAGTATTACTGAAATCTGCAGAGGGCG	1148
Qy	361	AsnLeuLySGlyGluSerIleTrpLysLeuGluTyrIleLeuThrGlnThrTyrAspIle	380
Db	1149	AATCTAAAGGAGAGTCCATCTGGAAGCTGGAGTATATCCTGACCCAGACCTACGACATT	1208
Qy	381	GluAspLeuGlnProGluSerLeuTyrGlyLeuAlaLysGlnPheThrIleLeuAspSer	400
Db	1209	GAAGATTTGCAGCCGAAAGTTTATATGATTAAGCTAAACAATTACAATCTAGACAGT	1268
Qy	401	LysGlnPheIleLysTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCys	420
Db	1269	AAGCAGTTTATAAATACTACAATTAATCTTTGTGAGTATGACAGCAGTGTAAACATGT	1328

QY 421 AspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTyr 440  
 DB 1329 GATAAGACATGTAAGGCCCTTGCAATTGTGCAATTATGAATCTTGATATAATTCTAT 1388  
 QY 441 AlaAspCysLeuLysGlnLeuTyrIleLeuLysHisAsnTyr 453  
 DB 1389 GCAGATTGCTCAACACAGCTTTATATAAAGCACAAATTAC 1427  
 RESULT 5  
 ADB90834 ID ADB90834 standard; cDNA; 1764 BP.  
 XX ADB90834;  
 AC 04-DEC-2003 (first entry)  
 DT  
 XX  
 DE Human cDNA encoding hydrolase-like molecule, HHLM 5, INCYTE 1376382.  
 XX  
 KW Human; hydrolase-like molecule; HHLM; cell proliferation disorder;  
 KW arteriosclerosis; atherosclerosis; bursitis; psoriasis; cancer;  
 KW autoimmune disorder; AIDS; Addison's disease;  
 KW adult respiratory distress syndrome; anaemia; asthma; diabetes mellitus;  
 KW ss; gene.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6518029-B1.  
 XX  
 PD 11-FEB-2003.  
 XX  
 PF 07-JUL-2000; 2000US-00612473.  
 XX  
 PR 06-FEB-1998; 98US-00013881.  
 XX  
 PA (INCY-) INCYTE GENOMICS INC.  
 XX  
 PI Bandman O, Lal P, Hillman JL, Corley NC, Guegler KJ, Shah P;  
 XX  
 DR WPI; 2003-742789/70.  
 DR P-PSDB; ADB90826.  
 PT  
 PT New human hydrolase-like molecules, useful for treating or preventing  
 PT cell proliferation disorders (e.g. atherosclerosis or cancers) and  
 PT autoimmune disorders (e.g. AIDS, Addison's disease, anemia and  
 PT diabetes mellitus).  
 XX  
 PS Example 6; Col 65-68; 55pp; English.  
 XX  
 CC The invention relates to a new isolated polypeptide comprising a human  
 CC hydrolase-like molecule, termed HHLM-8 appearing as ADB90822 - ADB90829,  
 CC a naturally occurring polypeptide comprising a sequence which is at least  
 CC 81% identical the HHLM, a biologically active fragment of an HHLM or an  
 CC immunogenic fragment comprising at least 15 contiguous amino acids. Also  
 CC included are a composition comprising an HHLM and an excipient, a method  
 CC for screening a compound as an agonist or antagonist of HHLM (by exposing  
 CC a sample comprising HHLM to a compound, and detecting agonist or  
 CC antagonist activity in the sample), a method for screening a compound  
 CC that specifically binds to HHLM (by combining HHLM with at least one test  
 CC compound, and detecting binding of HHLM to the test compound) and a  
 CC method for screening a compound that modulates the activity of HHLM. The  
 CC human hydrolase-like molecules (HHLM), agonists and antagonists useful  
 CC for treating or preventing cell proliferation disorders (e.g.  
 CC arteriosclerosis, atherosclerosis, bursitis, psoriasis, and cancers) and  
 CC autoimmune disorders (e.g. AIDS, Addison's disease, adult respiratory  
 CC distress syndrome, anaemia, asthma and diabetes mellitus). The HHLM  
 CC polypeptides are useful in preparing antibodies that specifically bind to  
 CC the polypeptides. Nucleic acids encoding HHLM are useful in generating  
 CC probes for mapping naturally occurring genomic sequences, in detecting  
 CC differences in the chromosomal location due to translocation or  
 CC inversion, and in screening libraries of compounds in drug screening  
 CC techniques. The present sequence encodes an HHLM of the invention.  
 XX

Seq	Sequence	1764 BP; 537 A; 356 C; 344 G; 527 T; 0 U; 0 Other;
Alignment Scores:		
Pred. No.:	1.17e-223	Length: 1764
Score:	2422.00	Matches: 452
Percent Similarity:	99.78%	Conservative: 0
Best Local Similarity:	99.78%	Mismatches: 1
Query Match:	99.79%	Indels: 0
DB:	10	Gaps: 0
US-09-823-119B-1 (1-453) x ADB90834 (1-1764)		
QY	1 MetAlaleuValArgAlaleuValCysCysleuLeuThrAlaTrpHisCysArgSergly	20
Db	69 ATGCGCGCTGGTGGCGGCACTCGTGTGCTGCTGCTGACTGCCTGGCACTGCCGCTCCGGC	128
QY	21 LeuGlyLeuProValAlaProAlaGlyGlyArgAsnProProProAlaIleGlyGlnPhe	40
Db	129 CTCGGGCTGCCGCTGGCGCCCGCAGCGGCAAGAACTCTCCTCCGCGCATAGACAGTTT	188
QY	41 TrpHisValThrAspLeuHisLeuAspProThrTrpHisIleThrAspAspHisThrLys	60
Db	189 TGGCATGTGACTGACTTACACTTGAACCTTACCCTTACACATCACAGATGACCAACAAA	248
QY	61 ValCysAlaSerSerLysGlyAlaAsnAlaSerAsnProGlyProPheGlyAspValLeu	80
Db	249 GTGTGTGCTTCATCTAAAGGTGCAATGCCCTCCAACCCCTGGCCCTTTGGAGATGTTCTG	308
QY	81 CysAspSerProTyrGlnLeuIleLeuSerAlaPheAspPheIleLysAsnSerglyGln	100
Db	309 TGTGATTTCTCCATATCACTATTTGTGCAGCATTTGATTTTATTAATAATCTCGACAA	368
QY	101 GluAlaSerPheMetIleTrpThrGlyAspSerProProHisValProValProGlyLeu	120
Db	369 GAAGCATCTTTCATGATATGGA CAGGGGATAGCCCACTCATGTCTCTGTACTGAACTC	428
QY	121 SerThrAspThrValIleAsnValIleThrAsnMetThrThrThrIleGlnSerLeuPhe	140
Db	429 TCAACAGACACTGTTATAATGTGATCACTAATATGACAAACCAACCATCCAGAGTCTCTT	488
QY	141 ProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrTrpProGlnAspGlnLeu	160
Db	489 CCAATCTCCAGGTTTTCCCTGGCTGGGTAACTGACTGACTATTGGCCACAGATCAACTG	548
QY	161 SerValValThrSerLysValTyrAsnAlaValAlaAsnLeuTrpLysProTrpLeuAsp	180
Db	549 CCTGTAGTCACACAGTAAGTGTACAAATGACGACAAACCTCTGAAACCATGGCTAGAT	608
QY	181 GluGluAlaIleSerThrLeuArgLysGlyGlyPheTyrSerGlnLysValThrThrAsn	200
Db	609 GAAGAGCTATTAGTACTTTAAGGAAGGTGGTTTTTATTACAGAAAGTTACAACTAAT	668
QY	201 ProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrTyrGlyProAsnIleMetThr	220
Db	669 CCAAACTTGAAGATCATCAGTCTAAACACAAACTTGTACTACGGCCCAATATATATGACA	728
QY	221 LeuAsnLysThrAspProAlaAsnGlnPheGluTrpLeuGluSerThrLeuAsnAsnSer	240
Db	729 CTGAACAAGACTGACCCAGCCAAACAGTTTGAATGGCTAGAAAAGTACATTGACAACACTCT	788
QY	241 GlnGlnAsnLysGlyLysValTyrIleIleAlaHisValProValGlyTyrLeuProSer	260
Db	789 CAGCAGAAATAAGAGAAGGTGTATATCATAGCACATGTTCCAGTGGGGTATCTGCCATCT	848
QY	261 SerGlnAsnIleThrAlaMetArgGluTyrTyrAsnGlnLysLeuIleAspIlePheGln	280
Db	849 TCACAGACATCACAGCAATGAGAAATGATAATGAGAAATTGATAGATATTTTCA	908
QY	281 LysTyrSerAspValIleAlaGlyGlnPheTyrGlyHisThrHisArgAspSerIleMet	300
Db	909 AAATACAGTATGTCAATTGACAGGACAAATTTTATGGACACACTCACAGAGACAGCATATG	968
QY	301 ValLeuSerAspLysLysGlySerProValAsnSerLeuPheValAlaProAlaValThr	320

|||||  
Db 969 GTCTTTCAGATATAAAGGAGTCCAGTAAATCTTTGTTGTGGCTCCTGTTACA 1028  
Qy 321 ProValLysSerValLeuGluLysGlnThrAsnProGlyIleArgLeuPheGlnTyr 340  
Db 1029 CCAGTGAAGAGTGTTTAGAAAAACAGACCACCAATCTGTATCAGACTGTTTCACTAT 1088  
Qy 341 AspProArgAspTyrLysLeuLeuAspMetLeuGlnTyrTyrLeuAsnLeuThrGluAla 360  
Db 1089 GATCCTCGTGAATTAATAATTATTGATATGTTGACGATTACTTGAATCTGACAGAGCG 1148  
Qy 361 AsnLeuLysGlyLysSerIleTrpLysLeuGluTyrIleLeuThrGlnThrTyrAspIle 380  
Db 1149 AATCTAAAGGAGAGTCCATCTGGAAGCTGAGTATATCTGACCCAGACTACGACATT 1208  
Qy 381 GluAspLeuGlnProGluSerLeuTyrGlyLeuAlaLysGlnPheThrIleLeuAspSer 400  
Db 1209 GAAGATTTCAGCCGCGAAAGTTTATATGATTAGCTAAACAATTACATCTTAGACAGT 1268  
Qy 401 LysGlnPheIleLysTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCys 420  
Db 1269 AAGCAGTTTATAATACTACAATTACTTCTTTGAGTTATGACAGCAGGTAAACATGT 1328  
Qy 421 AspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTyr 440  
Db 1329 GATAAGACATGTAAAGCCTTTCAGATTGTGCAATTATGAATCTTGATAATATTCCCTAT 1388  
Qy 441 AlaAspCysLeuLysGlnLeuTyrIleLysHisAsnTyr 453  
Db 1389 GCAGATTGCCCTCAACACAGCTTTATATAAGCACAATTAC 1427

RESULT 6  
ADJ45508  
ID ADJ45508 standard; cDNA; 1768 BP.

XX AC ADJ45508;

XX DT 06-MAY-2004 (first entry)

XX DE cDNA encoding LXR-ligand induced transcript seq id 39.

KW LXR; liver X receptor; cholesterol; gallstone; atherosclerosis;  
KW lipid storage disease; obesity; diabetes; hypercholesterolaemia;  
KW LXR-ligand induced 1; LXR1; human; LXR-ligand induced transcript;  
KW LXR regulated gene; ss; gene.

XX OS Homo sapiens.

XX PN US2004023276-A1.

XX PD 05-FEB-2004.

XX PF 02-MAY-2003; 2003US-00429160.

XX PR 03-MAY-2002; 2002US-0377714P.

XX PA (WARD/) WARD T R.

XX PA (MAOM/) MAO M.

XX PA (LINS/) LINSLEY P S.

XX PA (LUND/) LUND E.

XX PI Ward TR, Mao M, Linsley PS, Lund E;

XX DR WPI: 2004-224687/21.

XX DR P-PSDB; ADJ45509.

XX PT New purified liver X receptor (LXR) nucleic acids, useful for diagnosing  
PT a disease involving LXR activity, such as cholesterol gallstones,  
PT atherosclerosis, lipid storage diseases, obesity, diabetes, or  
PT hypercholesterolemia.

XX PS Example 1; SEQ ID NO 39; 141bp; English.

CC The invention describes a purified nucleic acid comprising a fully  
CC defined sequence of 1586 bp (SEQ ID NO: 1) as given in the specification,  
CC or its complement. The methods and compositions are useful for diagnosing  
CC a disease or disorder involving LXR (liver X receptor) activity in a  
CC sample by detecting an increase or decrease in the transcript level  
CC relative to the amount present in an analogous sample from a subject not  
CC having the disease or disorder or not subjected to therapy, wherein the  
CC disease or disorder is cholesterol gallstones, atherosclerosis, lipid  
CC storage diseases, obesity, diabetes, or hypercholesterolaemia. They are  
CC also used to identify a compound that changes LXR activity, wherein the  
CC compound changes the estimated level of LXR activity in a sample from the  
CC subject contacted with the compound relative to the estimated level of  
CC LXR activity in an analogous sample from the subject not contacted with  
CC the compound. This sequence encodes an LXR regulated protein.

XX SQ Sequence 1768 BP; 540 A; 358 C; 346 G; 524 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.17e-223 Length: 1768  
Score: 2422.00 Matches: 452  
Percent Similarity: 99.78% Conservative: 0  
Best Local Similarity: 99.78% Mismatches: 1  
Query Match: 99.79% Indels: 0  
DB: 12 Gaps: 0

US-09-823-119B-1 (1-453) x ADJ45508 (1-1768)

Qy 1 MetAlaLeuValArgAlaLeuValCysCysLeuLeuThrAlaTrpHisCysArgSerGly 20

Db 78 ATGCGCGTGTGGCGCGCACTCGTGTGCTGCTGCTGACTGCTGCGCACTGCCGCTCCGCGC 137

Qy 21 LeuGlyLeuProValAlaProAlaGlyGlyArgAsnProProProAlaIleGlyGlnPhe 40

Db 138 CTCGGGCTGCGCGCGCGCGCGCGCGAGCAAGATCCTCCTCCGGGATAGACAGATT 197

Qy 41 TrpHisValThrAspLeuHisLeuAspProThrTyrHisIleThrAspAspHisThrLys 60

Db 198 TGGCATGTGACTGACTTACACTTAGACCTTACTTACCACATCAGACACACAAAA 257

Qy 61 ValCysAlaSerSerLysGlyAlaAsnAlaSerAsnProGlyProPheGlyAspValLeu 80

Db 258 GTGTGTGCTTCATCTAAAGGTGCAATGCTTCAACCTGCGCTTTTGGAGATGTTCTG 317

Qy 81 CysAspSerProTyrGlnLeuIleLeuSerAlaPheAspPheIleLysAsnSerGlyGln 100

Db 318 TGTGATTCCTCATATCAACTTATTGTCAGCATTTGATTATTATAAAATTCTGACAA 377

Qy 101 GluAlaSerPheMetIleTrpThrGlyAspSerProProHisValProValProGluLeu 120

Db 378 GAAGCATCTTCATGATATGACAGGGGATAGCCACCTCATGTTCCTGTACTGACTC 437

Qy 121 SerThrAspThrValIleAsnValIleThrAsnMetThrThrThrIleGlnSerLeuPhe 140

Db 438 TCAACAGACACTGTTATTAATGTGATCACTAATATGACAAACCACTCCAGAGTCTTT 497

Qy 141 ProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrTrpProGlnAspGlnLeu 160

Db 498 CCAATCTCCAGGTTTCCCTGCGCTGGGTAACTAGACTATTGGCCACAGGATCAACTG 557

Qy 161 SerValValThrSerLysValTyrAsnAlaValAlaAsnLeuTrpLysProTrpLeuAsp 180

Db 558 CCTGTAGTACCAAGTAAAGTACAAATGACAGCAAACTCTGGAACCATGGCTAGAT 617

Qy 181 GluGluAlaIleSerThrLeuArgLysGlyGlyPheTyrSerGlnLysValThrThrAsn 200

Db 618 GAAGAAGCTATTAGTACTTTAAGGAAGGTGTTTATTATTCACAGAAAGTTACAATAAT 677

Qy 201 ProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrTyrGlyProAsnIleMetThr 220

Db 678 CCAACCTTAGATCATCAGTCTTAACACAACTGTACTACGCGCAATATATATGACA 737

Qy 221 LeuAsnLysThrAspProAlaAsnGlnPheGluTrpLeuGluSerThrLeuAsnAsnSer 240



Db 738 CTGAACAAGACTGACCCAGCAACCACTGTTGAATGGCTAGAAAGTACATTGAACAACACTCT 797  
QY 241 G|N|G|N|A|S|n|L|y|S|G|L|u|L|y|S|V|a|I|T|y|r|I|e|I|e|A|H|I|S|V|a|P|r|o|V|a|I|G|I|T|y|r|L|e|u|P|r|o|S|e|r 260  
Db 798 CAGCAGAATAAGAGAGAGGTGTATATCATAGACATGTTCCAGTGGGGTATCTGCCATCT 857  
QY 261 SerGlnAsnIleThrAlaMetArgGluTyrTyrAsnGluLysLeuIleAspIlePheGln 280  
Db 858 TCACAGACATCACGCAATGAGAGATACTATAATGAGAATTGATGATATTTTCA 917  
QY 281 LysTyrSerAspValIleAlaGlyGlnPheTyrGlyHisThrHisArgAspSerIleMet 300  
Db 918 AAATACAGTGAATGTCATTGCGAGACAATTTTATGACACACTCACAGACAGACATTATG 977  
QY 301 ValLeuSerAspLysLysGlySerProValAsnSerLeuPheValAlaProAlaValThr 320  
Db 978 GTTCTTCAGATAAAAAAGGAAGTCCAGTAATTTCTTTGTTGGCTCTGCTGTAC 1037  
QY 321 ProValLysSerValleuGluLysGlnThrAsnAsnProGlyIleArgLeuPheGlnTyr 340  
Db 1038 CCAGTGAAGAGTGTTTAGAAAAACAGACCAACAATCCGTGATCAGACTGTTTCAGTAT 1097  
QY 341 AspProArgAspTyrLysLeuLeuAspMetLeuGlnTyrTyrLeuAsnLeuThrGluAla 360  
Db 1098 GATCCTCGTATATAATTAATTGATATGTTGACGATTAATTGATCGACAGAGCG 1157  
QY 361 AsnLeuLysGlyGlnSerIleTrpLysLeuGluTyrIleLeuThrGlnThrTyrAspIle 380  
Db 1158 AATCTAAGGAGAGATCCATCTGGAAGCTGGAGTATATCCTGACCCAGACCTACGACATT 1217  
QY 381 GluAspLeuGlnProGluSerLeuTyrGlyLeuAlaLysGlnPheThrIleLeuAspSer 400  
Db 1218 GAAGATTTGCAGCCGGAAGTTTATATGATTAAGCTAAACAATTACATCTAGACAGT 1277  
QY 401 LysGlnPheIleLysTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCys 420  
Db 1278 AAGCAGTTTATAAATACTACAATTACTTCTTGTGAGTTATGACAGCAGTGTAAACATGT 1337  
QY 421 AspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTyr 440  
Db 1338 GATAAGACATGTAAAGCCCTTCAGATTGTGCAATTATGAATCTGATAATATTTCTCTAT 1397  
QY 441 AlaAspCysLeuLysGlnLeuTyrIleLysHisAsnTyr 453  
Db 1398 GCAGATTGCCCTCAACAACAGCTTATATAAGCACAATTAC 1436  
RESULT 7  
AAS62765 standard; cDNA; 1783 BP.  
XX AAS62765;  
AC AAS62765;  
DT 14-FEB-2002 (first entry)  
XX  
DE cDNA sequence #552 encoding novel human secreted protein.  
XX  
KW Human secreted protein; hyperproliferative disorder; autoimmune disorder;  
KW immune deficiency disorder; blood disorder; inflammatory disorder;  
KW infectious disorder; gene therapy; antimicrobial; hepatotropic;  
KW immunosuppressive; antirheumatic; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200177291-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 29-MAR-2001; 2001WO-US010485.  
XX  
PR 06-APR-2000; 2000US-0195604P.  
XX  
PA (GEMV ) GENETICS INST INC.  
XX

PI Wong GG, Clark HF, Fechtel K, Agostino MJ, Howes SH, Resnick RJ;  
PI Gulukota K, Graham JR;  
XX  
DR WPI; 2002-010900/01.  
XX  
PT New polynucleotides encoding secreted proteins useful for treating e.g.  
PT asthma, HIV and Crohn's disease.  
XX  
PS Claim 1; Page 356; 391pp; English.  
XX  
CC The present invention relates to the isolation of novel cDNA sequences  
CC which encode human secreted proteins. The cDNA sequences have been  
CC derived from a variety of human tissues. The invention also provides a  
CC method for producing proteins from these polynucleotide sequences. The  
CC proteins are useful for identifying compounds that modulate their  
CC activity and production, and the cell is also useful for identifying  
CC compounds that modulate expression of the polynucleotide sequences  
CC encoding the secreted proteins. The sequences of the invention are useful  
CC for treating diseases such as hyperproliferative disorders (e.g. cancer),  
CC immune deficiency disorders (e.g. severe combined immunodeficiency  
CC (SCID)), autoimmune disorders (e.g. multiple sclerosis), blood disorders  
CC (e.g. thrombocytopaenia), inflammatory disorders (e.g. arthritis) and  
CC infectious disorders (e.g. hepatitis). The polynucleotide sequences of  
CC the invention are also useful in gene therapy. AAS62214-AAS62838  
CC represent the cDNA sequences of the invention that encode for novel human  
CC secreted proteins  
XX  
SQ Sequence 1783 BP; 523 A; 376 C; 348 G; 536 T; 0 U; 0 Other;  
XX  
Alignment Scores:  
Pred. No.: 8.77e-223 Length: 1783  
Score: 2413.00 Matches: 451  
Percent Similarity: 99.56% Conservative: 0  
Best Local Similarity: 99.56% Mismatches: 2  
Query Match: 99.42% Indels: 0  
DB: 6 Gaps: 0  
US-09-823-119B-1 (1-453) x AAS62765 (1-1783)  
QY 1 MetAlaLeuValAlaGlaLeuValCysCysLeuLeuThrAlaTrpHisCysArgSerGly 20  
Db 113 ATGGCGCTGGTGGCGCGACACTGCTGTGCTGCTGCTGACTGCTGCTGCTGCCGCTCCGCC 172  
QY 21 LeuGlyLeuProValAlaProAlaGlyGlyArgAsnProProProAlaIleGlyGlnPhe 40  
Db 173 CTCGGGCTGCCCGTGGCGCCCGCATGCCGAGGAATCCTCTCCGGCGATAGACAGATT 232  
QY 41 TrpHisValThrAspLeuHisLeuAspProThrTyrHisIleThrAspAspHisThrLys 60  
Db 233 TGGCATGTGACTGACTTACACTTAGACCTTACTTACCACATCACAGATGACCACAAAA 292  
QY 61 ValCysAlaSerSerLysGlyAlaAsnAlaSerAsnProGlyProPheGlyAspValLeu 80  
Db 293 GTGTGTGCTTCATCTAAAGGTGCAATGCCTCCAAACCTGGCCCTTTGGAGATGTTCTG 352  
QY 81 CysAspSerProTyrGlnLeuIleLeuSerAlaPheAspPheIleLysAsnSerGlyGln 100  
Db 353 TGTGATCTCCATATCATCACTTAATTTGTGACGATTTGATTTATAAAATTCGACAA 412  
QY 101 GluAlaSerPheMetIleTrpThrGlyAspSerProProHisValProValProGluLeu 120  
Db 413 GAAGCATCTTTCATGATATGACAGGGGATAGCCCACTCATGTCTCTGTACCTGAAC 472  
QY 121 SerThrAspThrValIleAsnValIleThrAsnMetThrThrThrIleGlnSerLeuPhe 140  
Db 473 TCAACAGACACTGTATATAATGTGATCACTAATATGACAAACCAATCCAGAGTCTCTT 532  
QY 141 ProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrTrpProGlnAspGlnLeu 160  
Db 533 CCAATCTCCAGGTTTCCCTGGCGTGGGTATCATGACTATGGCCACAGATCAACTG 592  
QY 161 SerValValThrSerLysValTyrAsnAlaValAlaAsnLeuTrpLysProTrpLeuAsp 180



Db 593 CCTGTAGTCACCAGTAAGTGTACAATGCAGTAGCAAACTCTGMAAACCATGGCTAGAT 652  
Qy 181 GUGLUALAIESErThrLeuArglySGlyGlyPheTyrSerGlnLysValThrThrAsn 200  
Db 653 GAAGAAGCTATTAGTACTTTAAGGAAGGTGGTTTATTTCACAGAAGATTACAATAAT 712  
Qy 201 ProAsnLeuArglleIErSerLeuAsnThrAsnLeuTyrTyrGlyProAsnIleMetThr 220  
Db 713 CCAACCTTAGGATCATCAGTCTAAACACAACTTGTACTACGGCCCAATATATGACA 772  
Qy 221 LeuAsnLysThrAspProAlaAsnGlnPheGluTyrPleuGluSerThrLeuAsnAsnSer 240  
Db 773 CTGAACAAGACTGACCCAGCCAAACAGTTGAATGGCTAGAAAGTACATTGAACAACACTCT 832  
Qy 241 GlnGlnAsnLysGlyLysValTyrIleIleAlaHisValProValGlyTyrLeuProSer 260  
Db 833 CAGCAGAAATAGGAGAGGTGTATATCATAGCAGATGTTCCAGTGGGTATCTGCCATCT 892  
Qy 261 SerGlnAsnIleThrAlaMetArgGluTyrTyrAsnGlnLysLeuIleAspIlePheGln 280  
Db 893 TCACAGAACATCACAGCAATGAGAGAACTAATAAGAAATGATAGATATTTTCAA 952  
Qy 281 LysTyrSerAspValIleAlaGlyGlnPheTyrGlyHisThrHisArgAspSerIleMet 300  
Db 953 AAATACAGTGTATGCTTGCAGAGACATTTTATGACACACTCACAGAGACGACATATATG 1012  
Qy 301 ValLeuSerAspLysLysGlySerProValAsnSerLeuPheValAlaProAlaValThr 320  
Db 1013 GTTCTTCAGATAAAAAGGAAGTCCAGTAATTTCTTTGTGGCTCCTGCTGTTACA 1072  
Qy 321 ProValLysSerValLeuGlnLysGlnThrAsnAsnProGlyIleArgLeuPheGlnTyr 340  
Db 1073 CCAGTGAAGAGTGTTTTGAAGAAACAGACCAACATCTCTGTATCAGACTGTTTCAGTAT 1132  
Qy 341 AspProArgAspTyrLysLeuLeuAspMetLeuGlnTyrTyrLeuAsnLeuThrGluAla 360  
Db 1133 GATCCTCGTATTAATAATTATTGGATATGTTGCAGTATTACTGAATCTGACAGAGCG 1192  
Qy 361 AsnLeuLysGlyGlySerIleTyrPheLysLeuGlnTyrIleLeuThrGlnThrTyrAspIle 380  
Db 1193 AATCTAAAGGAGAGTCCATCTGGAAGCTGAGTATATCTGACCCAGACCTACGACATTT 1252  
Qy 381 GluAspLeuGlnProGluSerLeuTyrGlyLeuAlaLysGlnPheThrIleLeuAspSer 400  
Db 1253 GAAGATTGACGCCGGAAGTTTATATGATTAGCTTAACAATTACCAATCTTACAGACACT 1312  
Qy 401 LysGlnPheIleLysTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCys 420  
Db 1313 AAGCAGTTTATATACTACTCAATTACTTCTTGTGAGTTATGACAGCAGTGAACATGT 1372  
Qy 421 AspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTyr 440  
Db 1373 GATAGACATGTAAAGCCTTTCAGATTGTGCAATTATGAATCTTGATAATATTCTCTAT 1432  
Qy 441 AlaAspCysLeuLysGlnLeuTyrIleLysHisAsnTyr 453  
Db 1433 GCAGATTGCCCTCAACAGCTTATATAAGCACAAATTAC 1471  
RESULT 8  
AAS94849  
ID AAS94849 standard; DNA; 1746 BP.  
XX  
AC AAS94849;  
XX  
DT 14-FEB-2002 (first entry)  
XX  
DE Human DNA sequence #104 expressed during foam cell differentiation.  
XX  
KW Human; foam cell differentiation; atherosclerosis; cerebral stroke;  
KW cardiovascular disorder; coronary artery disease; gene therapy; ds.  
XX  
OS Homo sapiens.  
XX

PN WO200177389-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 04-APR-2001; 2001WO-US011128.  
XX  
PR 05-APR-2000; 2000US-0195106P.  
XX  
PA (INCY-) INCYTE GENOMICS INC.  
XX  
PI Shiffman D, Somogyi R, Lawn R, Selthamer JJ, Porter GJ, Mikita T;  
PI Tai J;  
XX  
DR WPI; 2002-010925/01.  
XX  
PT Composition useful for diagnosis of conditions, disorders or diseases  
PT associated with atherosclerosis, comprises several polynucleotides that  
PT are differentially expressed in foam cell development.  
XX  
PS Claim 1; Page 156; 315pp; English.  
XX  
CC The present invention relates to the isolation of human polynucleotide  
CC sequences that are differentially expressed during foam cell  
CC differentiation. The polynucleotide sequences of the invention or a  
CC composition comprising these polynucleotides are useful as a high  
CC throughput method for detecting altered expression of one or more  
CC polynucleotides in a sample. The polynucleotides can be used in the  
CC diagnosis of disorders associated with foam cell development such as  
CC atherosclerosis, cerebral stroke, and cardiovascular disorders such as  
CC coronary artery disease. The polynucleotide sequences can also be used as  
CC PCR primers and probes. The polynucleotides of the invention are also  
CC useful in gene therapy. AAS94746-AAS95021 represent the human  
CC polynucleotide sequences of the invention which are differentially  
CC expressed during foam cell differentiation  
XX  
SQ Sequence 1746 BP; 521 A; 356 C; 342 G; 527 T; 0 U; 0 Other;  
Alignment Scores:  
Pred. No.: 2,07e-222 Length: 1746  
Score: 2409.00 Matches: 452  
Percent Similarity: 99.56% Conservative: 0  
Best Local Similarity: 99.56% Mismatches: 1  
Query Match: 99.26% Indels: 1  
DB: 6 Gaps: 0  
US-09-823-119B-1 (1-453) x AAS94849 (1-1746)  
Qy 1 MetAlaLeuValArgAlaLeu-ValCysLeuLeuThrAlaThrHisCysArgSerG1 20  
Db 69 ATGGCGCTGGTGGCGCGCACTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 128  
Qy 20 yLeuGlyLeuProValAlaProAlaGlyGlyArgAsnProProProAlaIleGlyGlnPh 40  
Db 129 CCTGGGCTGGCG 188  
Qy 40 eTrpHisValThrAspLeuHisLeuAspProThrTyrHisIleThrAspAspHisThrLy 60  
Db 189 TTGGCATGTGACTGACTTACACTTAGACCTTACCATCATCAGATGACACACAAA 248  
Qy 60 sValCysAlaSerSerLysGlyAlaAsnAlaSerAsnProGlyProPheGlyAspValLe 80  
Db 249 AGTGTGTCTTCATCTAAAGGTGCAATGCTCCCAACCCCTGGCCCTTTTGGAGATGTTCT 308  
Qy 80 uCysAspSerProTyrGlnLeuIleLeuSerAlaPheAspPheIleLysAsnSerGlyG1 100  
Db 309 GTGTGATTCCTCATATCAACTTATTTGTTCAGCATTTGATTTTATTAATAATTCTGAGACA 368  
Qy 100 nGluAlaSerPheMetIleTyrThrGlyAspSerProProHisValProValProGluLe 120  
Db 369 AGAAGCATTTTTCATGATATGACAGGGGATAGCCCACTCATGTTCTGTACTGAACT 428  
Qy 120 uSerThrAspThrValIleAsnValIleThrAsnMetThrThrThrIleGlnSerLeuPh 140

Db 429 CTCACAGACACTGTTAATAATGTGATCACTAATATAGCAACACCATCCAGACTCTCTT 488  
QY 140 eProAsnleuGlnValPheProAlaIleuGlyAsnHisAspTyrTrpProGlnAspGlnIle 160  
Db 489 TCCAATATCTCAGGTTTCCCTGCGCTGGGTAATCATGACTATTTGGCCACAGATCAACT 548  
QY 160 uSerValValThrSerLysValTyrAsnAlaValAlaAsnLeuTrpLysProTrpLeuAs 180  
Db 549 GCCTGTAGTCACCAATAAGTGTACATGCAAGCAACCTCTGGAAACCATGGCTAGA 608  
QY 180 pGluGluAlaIleSerThrLeuArgLysGlyGlyPheTyrSerGlnLysValThrThrAs 200  
Db 609 TGAAGAAGCTATTAGTACTTTAAGGAAAGGTGTTTATTTCACAGAAAGTTACAACCTAA 668  
QY 200 nProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrTyrGlyProAsnIleMetTh 220  
Db 669 TCCAACCTTAGGATCATCAGCTTAACACAACTGTACTACGGCCCAATATTAATGAC 728  
QY 220 rLeuAsnLysThrAspProAlaAsnGlnPheGluTrpLeuGluSerThrLeuAsnAsnSe 240  
Db 729 ACTGAACAAGACTGACCCAGCCCAACCAAGTTGTAATGGCTAGAAAGTACATTGAACAAC 788  
QY 240 rGlnGlnAsnLysGluLysValTyrIleIleAlaHisValProValGlyTyrLeuProSe 260  
Db 789 TCAGCAGAATAAGAGAAGGTGTATATCATATGACACATGTTCCAGTGGGTATCTGCCATC 848  
QY 260 rSerGlnAsnIleThrAlaMetArgGluTyrTyrAsnGluLysLeuIleAspIlePheG1 280  
Db 849 TTCACAGACATCATCAGCAATGAGAGATACTATAATGAGAAATTGATGATATTTTCA 908  
QY 280 nLysTyrSerAspValIleAlaGlyGlnPheTyrGlyHisThrHisArgAspSerIleMe 300  
Db 909 AAAATACAGTGTATGTCATTGCAGGACAAATTTATGACACACTCACAGACACAGCATTAT 968  
QY 300 tValLeuSerAspLysLysGlySerProValAsnSerLeuPheValAlaProAlaValTh 320  
Db 969 GGTCTTTCAGATTAATAAGGAAGTCCAGTAATTCCTTGTGTTGCTCTGCTGTTAC 1028  
QY 320 rProValLysSerValleuGluLysGlnThrAsnAsnProGlyIleArgLeuPheGlnTy 340  
Db 1029 ACCAGTGAAGAGTGTTTTAGAAAAACAGACCACCAATCCTGTATCAGACTGTTTCAGTA 1088  
QY 340 rAspProArgAspTyrLysLeuLeuAspMetLeuGlnTyrTyrLeuAsnLeuThrGluAl 360  
Db 1089 TGATCCTCGTGTATTAATATTATGATATGTGCAGTATTACTTGAATCTGACAGAGGC 1148  
QY 360 aAsnLeuLysGlyGluSerIleTrpLysLeuGluTyrIleLeuThrGlnThrTyrAspI1 380  
Db 1149 GAATCTAAAGGAGAGTCCATCTGGAAGCTGGAGTATATCTGACCCAGACTACGACAT 1208  
QY 380 eGluAspLeuGlnProGluSerLeuTyrGlyLeuAlaLysGlnPheThrIleLeuAspSe 400  
Db 1209 TGAAGATTTCAGCCGGAAGTTTATATGATTAGCTTAACAATTACCAATCTTAGACAG 1268  
QY 400 rLysGlnPheIleLysTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCy 420  
Db 1269 TAAGCAGTTTATTAATACTACCAATTACTTCTTGTGAGTTATGACAGCAGTGAACATG 1328  
QY 420 sAspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTy 440  
Db 1329 TGATTAAGACATGTAAAGCCTTTCAGATTGTGCAATTATGAATCTTGATAATATTCCCTA 1388  
QY 440 rAlaAspCysLeuLysGlnLeuTyrIleLysHisAsnTyr 453  
Db 1389 TGCAGATTGCCTCAACAGCTTTATATATAAGCACAATTAC 1428

RESULT 9  
ADF81833  
ID ADF81833 standard; DNA; 2505 BP.  
XX ADF81833;  
AC  
XX  
DT 26-FEB-2004 (first entry)

XX DE Leukaemia-related DNA sequence #2389.  
XX KW Cytostatic; Gene therapy; leukaemia; ss.  
XX OS Unidentified.  
XX PN WO2003039443-A2.  
XX PD 15-MAY-2003.  
XX PF 04-NOV-2002; 2002WO-EP012303.  
XX PR 05-NOV-2001; 2001EP-00126244.  
XX PR 30-APR-2002; 2002EP-00009758.  
XX PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.  
XX PA (UYLU-) UNIV LUDWIG MAXIMILIANS.  
XX PA (HAFE/) HAFERLACH T.  
XX PA (SCHO/) SCHOCH C.  
XX PA (KERN/) KERN W.  
XX PI Haferlach T, Schoch C, Kern W, Kohlmann A, Schmittger S, Dugas M;  
PI Bils R, Brors B, Mergenthaler S;  
XX DR WPI; 2003-505037/47.  
XX XX  
PT Determining the subtype of leukemia cells and whether a patient sample  
PT contains leukemia cells or other cells, useful for treating leukemia,  
PT comprises determining the expression profile of a group of markers in a  
PT patient sample.  
XX PS  
PS Disclosure; SEQ ID NO 2389; 2938bp; English.  
XX CC  
CC The present invention relates to a method (M1) for determining the  
CC subtype of leukaemia cells and whether a patient sample contains  
CC leukaemia cells. The method comprises determining the expression profile  
CC of a group of markers in a patient sample. The method is useful for  
CC determining the presence of leukaemia cells, its types or subtypes, and  
CC for the preparation of a medicament for treating leukaemia.  
XX SQ  
SQ Sequence 2505 BP; 730 A; 537 C; 482 G; 737 T; 0 U; 19 Other;  
Alignment Scores:  
Pred. No.: 5.7e-217 Length: 2505  
Score: 2355.00 Matches: 445  
Percent Similarity: 98.02% Conservative: 0  
Best Local Similarity: 98.02% Mismatches: 8  
Query Match: 97.03% Indels: 1  
DB: 10 Gaps: 0  
US-09-823-119B-1 (1-453) x ADF81833 (1-2505)  
QY 1 MetAlaLeuValArgAlaLeuValCysCys-LeuLeuThrAlaTrpHisCysArgSerG1 20  
Db 590 ATGGCGCTGGTGGCGGCACTGCTGCTGCCNTGCTGACTGCGCTGGCACTGCCGCTCCGG 649  
QY 20 yLeuGlyLeuProValAlaProAlaGlyGlyArgAsnProPropProAlaIleGlyGlnPh 40  
Db 650 CCTCGGGCTGCCCGTGGCGCCCGCAGCGGCGAGAAATCCTCCTCGCGGAGATAGNAGTT 709  
QY 40 eTrpHisValThrAspLeuHisLeuAspProThrTyrHisIleThrAspAspHisThrLy 60  
Db 710 NTNNMATGTGACTGACTTACACTTACCTTACTTACCAACATGACAGATGACACACAAA 769  
QY 60 sValCysAlaSerSerLysGlyAlaAlaAsnAlaSerAsnProGlyPropPheGlyAspValle 80  
Db 770 AGTGTGTCTTCATCTAAAGGTGCAATGCCCTCCAAACCTGGCCCTTNTGAGATGTTCT 829  
QY 80 uCysAspSerProTyrGlnLeuIleLeuSerAlaPheAspPheIleLysAsnSerGlyG1 100  
Db 830 GTGTGATTCTCCATATCAACTTATTTGTGACGATTTGATTTTAATAAAATTCGACA 889

```

Qy 100 nGluAlaSerPheMetIleTrpThrGlyAspSerProPheIsvAlProValProGluLe 120
Db 890 AGAAGCATCTTTCATGATATGACAGGGGATAGCCACCTCATGTTCCTGTACTGAACT 949
Qy 120 uSerThrAspThrValIleAsnValIleThrAsnMetThrThrThrIleGlnSerLeuPh 140
Db 950 CTCAACAGACACTGTTATTAATGATGATCAATAATGACACACCACCACTCCAGAGTCTCTT 1009
Qy 140 eProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrTrpProGlnAspGlnLe 160
Db 1010 TCCAATCTCCAGGTTTCCCTGCGCTGGGTAAATCAATGACTATTGGCCACAGATCAACT 1069
Qy 160 uSerValValThrSerLysValTyrAsnAlaValAlaAsnLeuTrpLysProTrpLeuAs 180
Db 1070 GCCTGTAGTCAACAGTAAGAGTGTACAATGACAGTAAACCTTGGAACCATGGCTAGA 1129
Qy 180 pGluGluAlaIleSerThrLeuArgLysGlyGlyPheTyrSerGlnLysValThrThrAs 200
Db 1130 TGAAGAAGCTATTAGTACTTTAAGAAAGGTGTTTATTTCACAGAAAGTTACAACCTAA 1189
Qy 200 nProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrGlyProAsnIleMetTh 220
Db 1190 TCCAACCTTAGATCATCAGCTCTANACAACTTGTAATGAGGCCCAATATATATGAC 1249
Qy 220 rLeuAsnLysThrAspProAlaAsnGlnPheGluTrpLeuGluSerThrLeuAsnAsnSe 240
Db 1250 ACTGAACAAGACTGACCCAGCCAAACAGTTGAATGGCTAGAAAGTACATTGAACAACCTC 1309
Qy 240 rGlnGlnAsnLysGluLysValTyrIleIleAlaHisValProValGlyTyrLeuProSe 260
Db 1310 TCAGCAGAAATTAAGAGAGAGGTGTATATCATAGACATGTTCCAGTGGGTATCTGCCATC 1369
Qy 260 rSerGlnAsnIleThrAlaMetArgGluTyrTyrAsnGluLysLeuIleAspIlePheG1 280
Db 1370 TTCACAGAACTACACAGCAATGAGAAATCTATAATGAGAAATTGATGATATTTTCA 1429
Qy 280 nLysTyrSerAspValIleAlaGlyGlnPheTyrGlyHisThrHisArgAspSerIleMe 300
Db 1430 AAAATACAGTGTATGTCATTCAGAGCAATTTATGACACACTCAGACAGACAGCATTAT 1489
Qy 300 tValLeuSerAspLysLysGlySerProValAsnSerLeuPheValAlaProAlaValTh 320
Db 1490 GGTTCTTTCAGATAAAAAAGAGAGTCCAGTAATTTCTTGTGTTGGCTCCTGCTGTAC 1549
Qy 320 rProValLysSerValLeuGluLysGlnThrAsnAsnProGlyIleArgLeuPheGlnTy 340
Db 1550 ACCAGTGAAGAGTGTTTTGAAGAAACAGACCAACAATCCTGGTATCAGACTGTTCA 1609
Qy 340 rAspProArgAspTyrLysLeuLeuAspMetLeuGlnTyrTyrLeuAsnLeuThrGluAl 360
Db 1610 TGATCCTCGTGTATTATAATTATTGATATGTTGACAGTATTACTTGAATCTGACAGAGC 1669
Qy 360 aAsnLeuLysGlyGluSerIleTrpLysLeuGluTyrIleLeuThrGlnThrTyrAspI1 380
Db 1670 GAATCTAAAGGAGAGTCCATCTGAGAGCTGGAGTATATCTCGACCCAGACCTACGACAT 1729
Qy 380 eGluAspLeuGlnProGluSerLeuTyrGlyLeuAlaLysGlnPheThrIleLeuAspSe 400
Db 1730 TGAAGATTGCAAGCCGGAAGTTTATATGATTAAGCTAAACAATTTCATCCTAGACAG 1789
Qy 400 rLysGlnPheIleLysTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCy 420
Db 1790 TAAGCAGTTTATAAATACTACAATTACTTTCTTTGTGAGTTATGACAGCAGTGAACATG 1849
Qy 420 sAspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTy 440
Db 1850 TGATTAAGACATGTAAAGGCTTCAGATTGTCGAATTATGAATCTTGATTAATATTTCTTA 1909
Qy 440 rAlaAspCysLeuLysGlnLeuTyrIleLysHisAsnTyr 453
Db 1910 TGCAGATTGCCTCAAAACAGCTTATATATAAGCACAAATTAC 1949

```

RESULT 10

```

AAI61110
ID AAI61110 standard; cDNA; 1873 BP.
XX
AC AAI61110;
DT 22-OCT-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 5099.
XX
KW Human; nootropic; immunosuppressant; cyostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; ss.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US034263.
XX
PR 23-DEC-1999; 99US-00471275.
PR 21-JAN-2000; 2000US-00488725.
PR 25-APR-2000; 2000US-00552317.
PR 20-JUN-2000; 2000US-00598042.
PR 19-JUL-2000; 2000US-00620312.
PR 03-AUG-2000; 2000US-00653450.
PR 14-SEP-2000; 2000US-00662191.
PR 19-OCT-2000; 2000US-00693036.
PR 29-NOV-2000; 2000US-00727344.
XX
XX (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QA;
PI Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR P-PSDB; AAM41954.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders such
PT as central nervous system injuries.
XX
PS Claim 1; SEQ ID NO 5099; 10078bp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and the
CC encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cyostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders. Note: The sequence data for this patent did not form
CC part of the printed specification
XX
SQ Sequence 1873 BP; 596 A; 359 C; 335 G; 583 T; 0 U; 0 Other;

```

## Alignment Scores:

Pred. No.:	2,12e-204	Length:	1873
Score:	2223.00	Matches:	416
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	91.59%	Indels:	0
DB:	4	Gaps:	0



US-09-823-119B-1 (1-453) x AAI61110 (1-1873)

QY 38 G l y G l n P h e T r p H i s V a l T h r A s p l e u H i s l e u A s p P r o t h r T y r H i s l e T h r A s p A s p 57  
D b 303 G G A C A G T T T G C A T G T G A C T T G A C T T A G A C C C T A C T T A C C A C A T C A C A G A T G A C 362  
QY 58 H i s T h r l y s V a l C y s A l a S e r S e r l y s G l y A l a s n A l a S e r A s n P r o G l y P r o P h e G l y 77  
D b 363 C A C A C A A A G T G T G C T T C A T C T A A A G G T G C A A A T G C C T C C A A C C C T G G C C C T T T T G A 422  
QY 78 A s p V a l l e u C y s A s p S e r P r o T y r G l n l e u l e l e u S e r A l a P h e A s p P h e l l e l y s A s n 97  
D b 423 G A T G T T C T G T G A T T C C C A T A T C A A C T T A T T T G T C A G C A T T T G A T T T A T T A A A A A T 482  
QY 98 S e r G l y G l n G l u A l a S e r P h e M e t l e T r p T h r G l y A s p S e r P r o P r o H i s V a l P r o V a l 117  
D b 483 T C T G A C A G A G A G C A T C T T T C A T G A T A T G A C A G G G A T A G C C C A C C C A T G T T C C T G T A 542  
QY 118 P r o G l u l e u S e r T h r A s p T h r V a l l e a s n V a l l e T h r A s n M e t T h r T h r l l e G l n 137  
D b 543 C C T G A A C T C T C A C A G A C A C T G T T A T A A T G T G A T C A C T A A T A T G A C A A C C A C C A T C C A G 602  
QY 138 S e r l e u P h e P r o A s n l e u G l n V a l P h e P r o A l a l e u G l y A s n H i s A s p T y r T r p P r o G l n 157  
D b 603 A G T C T T T T C A A A T C T C C A G G T T T C C T G C G C T G G G T A A T C A T G A C T A T T G C C A C A G 662  
QY 158 A s p G l n l e u S e r V a l V a l T h r S e r l y s V a l T y r A s n A l a V a l A l a s n l e u T r p l y s P r o 177  
D b 663 G A T C A A C T G T C T A G T C A C C A G T A A A G T G A C A A T G C A G T A G C A A C C T C T G A A A C C A 722  
QY 178 T r p l e u A s p G l u G l u A l a l e S e r T h r l e u A r g l y s G l y P h e T y r S e r G l n l y s V a l 197  
D b 723 T G G T A G A T G A G A A G C T A T T A G A C T T T A A G A A A G G T G T T T T A T T C A C A G A A A G T T 782  
QY 198 T h r T h r A s n P r o A s n l e u A r g l l e l e S e r l e u A s n T h r A s n l e u T y r T y r G l y P r o A s n 217  
D b 783 A C A C T A A T C C A A C C T T A G A T C A T C A G T C T A A A C A C A A C C T T G T A C A G G C C C A A T 842  
QY 218 l l e M e t T h r l e u A s n l y s T h r A s p P r o A l a s n G l n P h e G l u T r p l e u G l u S e r T h r l e u 237  
D b 843 A T A A T G A C A C T G A C A G A C T G A C C C A G C C A A C C A G T T G A A T G C C T A G A A A G T A C A T T G 902  
QY 238 A s n A s n S e r G l n G l n A s n l y s G l u l y s V a l T y r l l e l e A l a H i s V a l P r o V a l G l y T y r 257  
D b 903 A A C A A C T C T C A G C A G A A T T A A G A G A G G T G T A T A T C A T A G C A C A T G T T C C A G T G G G G T A T 962  
QY 258 l e u P r o S e r S e r G l n A s n l l e T h r A l a M e l A r g l u T y r T y r A s n G l u l y s l e u l l e A s p 277  
D b 963 C T G C C A T C T T C A C A G A A C A T C A C A G C A A T G A G A A T A C T A T A A T G A G A A A T T G A T A G A T 1022  
QY 278 l l e P h e G l n l y s T y r S e r A s p V a l l e a l a G l y G l n P h e T y r G l y H i s T h r H i s A r g A s p 297  
D b 1023 A T T T T T C A A A A T A C A G T G A T G T C A T T G C A G G A C A A T T T A T G A C A C A C T C A C A G A G A C 1082  
QY 298 S e r l l e M e t V a l l e u S e r A s p l y s l y s G l y S e r P r o V a l A s n S e r l e u P h e V a l A l a P r o 317  
D b 1083 A G C A T A T G T T C T T T C A G A T A A A A A G A G A G T C C A G T A A A T T C T T T G T T G T G C T C C T 1142  
QY 318 A l a V a l T h r P r o V a l l y s S e r V a l l e u G l u l y s G l n T h r A s n A s n P r o G l y l l e A r g l e u 337  
D b 1143 G C T G T T A C A C A G T G A A G A G T G T T T A G A A A A C A G A C C A A C A A T C T G T A T C A G A C T G 1202  
QY 338 P h e G l n T y r A s p P r o A r g A s p T y r l y s l e u l e u A s p M e t l e u G l n T y r T y r l e u A s n l e u 357  
D b 1203 T T T C A G T A T G A T C C T C G T G A T T A A A T T A A T T G A T A T G T G C A G T A T T A C T T G A A T C T G 1262  
QY 358 T h r G l u A l a s n l e u l y s G l y l u S e r l e T r p l y s l e u G l u T y r l l e l e u T h r G l n T h r 377  
D b 1263 A C A G A G G C G A A T C T A A A G G A G A G A G T C C A T C T G A A G A C T G A G T A T C C T G A C C A G A C C 1322  
QY 378 T y r A s p l l e G l u A s p l e u G l n P r o G l u S e r l e u T y r G l y l e u A l a l y s G l n P h e T h r l l e 397

D b 1323 T A C G A C A T T G A A G A T T T G C A G C C G A A A G T T A T A T A T G A T T A G C T A A A C A A T T T A C A A T C 1382  
QY 398 l e u A s p S e r l y s G l n P h e l l e l y s T y r T y r A s n T y r P h e P h e V a l S e r T y r A s p S e r S e r 417  
D b 1383 C T A G A C A G T A A G C A G T T T A T A A A T A C A C A A T T A C T T C T T G T G A G T T A T G A C A G A C A G T 1442  
QY 418 V a l T h r C y s A s p l y s T h r C y s l y s A l a P h e G l n l l e C y s A l a l l e M e t A s n l e u A s p A s n 437  
D b 1443 G T A C A C T G T G A T A A G A C A T G T A A G C C T T T C A G A T T T G T G C A A T T A T G A A T C T T G A T A A T 1502  
QY 438 l l e S e r T y r A l a A s p C y s l e u l y s G l n l e u T y r l l e l y s H i s A s n T y r 453  
D b 1503 A T T C C T A T G C A G A T T G C C T C A A C A G C T T T A T A T A A A G C A C A A T T A C 1550  
RESULT 11  
AAI59324  
ID AAI59324 standard; cDNA; 1874 BP.  
XX  
AC AAI59324;  
XX  
DT 22-OCT-2001 (first entry)  
XX  
DE Human polynucleotide SEQ ID NO 1527.  
XX  
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;  
KW peripheral nervous system; neuropathy; central nervous system; CNS;  
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;  
KW leukaemia; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200153312-A1.  
XX  
PD 26-JUL-2001.  
XX  
PF 26-DEC-2000; 2000WO-US034263.  
XX  
PR 23-DEC-1999; 99US-00471275.  
PR 21-JAN-2000; 2000US-00488725.  
PR 25-APR-2000; 2000US-00552317.  
PR 20-JUN-2000; 2000US-00598042.  
PR 19-JUL-2000; 2000US-00620312.  
PR 03-AUG-2000; 2000US-00653450.  
PR 14-SEP-2000; 2000US-00662191.  
PR 19-OCT-2000; 2000US-00693036.  
PR 29-NOV-2000; 2000US-00727344.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QA;  
PI Zhou P, Goodrich R, Drmanac RT;  
XX  
DR WPI; 2001-442253/47.  
DR P-PSDB; AAM40168.  
XX  
PT Novel nucleic acids and polypeptides, useful for treating disorders such  
PT as central nervous system injuries.  
XX  
PS Claim 1; SEQ ID NO 1527; 10078bp; English.  
XX  
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and the  
CC encoded polypeptides (AAM38642-AAM42213) with nootropic,  
CC immunosuppressant and cytostatic activity. The polynucleotides are useful  
CC in gene therapy. A composition containing a polypeptide or polynucleotide  
CC of the invention may be used to treat diseases of the peripheral nervous  
CC system, such as peripheral nervous injuries, peripheral neuropathy and  
CC localised neuropathies and central nervous system diseases, such as  
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
CC utilisation of the activities such as: Immune system suppression,





of developing ovarian cancer involving inhibiting expression of a gene corresponding to a marker of the invention and a method of treating a patient afflicted with ovarian cancer comprising providing to cells of the patient an antisense oligonucleotide complementary to a marker of the invention. The markers are useful for assessing if a patient is afflicted with ovarian cancer, which involves comparing the level of expression of a marker in a patient sample and a normal level of expression of the marker in a control non-ovarian cancer sample. A difference between the expression levels indicates ovarian cancer. The level of expression of a marker corresponds to a secreted protein or to a transcribed polynucleotide or its portion. The level of expression of the marker is assessed by detecting the presence in the sample, a protein or protein fragment corresponding to the marker. The presence of protein or protein fragment is detected using an antibody that specifically binds with the protein or protein fragment. Alternatively, the level of expression of the marker is assessed by detecting the presence of a transcribed polynucleotide which anneals with the marker or anneals with a portion of the polynucleotide comprising the marker, under stringent conditions. The marker is also used for monitoring the progression of ovarian cancer in a patient which involves detecting expression of the marker in a patient sample at a first point in time, repeating the method at a subsequent time and comparing the level of expression. The method is carried out using an ovarian tissue sample. A composition comprising a marker, polypeptide or antibody of the invention is used to treat ovarian cancer. This sequence represents a human ovarian cancer DNA marker of the invention.

Sequence 2049 BP; 614 A; 392 C; 415 G; 617 T; 0 U; 11 Other;

Alignment Scores:	3.51e-179	Length:	2049
Pred. No.:	1962.50	Matches:	380
Score:	83.89%	Conservative:	0
Percent Similarity:	83.89%	Mismatches:	2
Best Local Similarity:	80.86%	Indels:	72
Query Match:	5	Gaps:	1
DB:			

US-09-823-119B-1 (1-453) X ADL62954 (1-2049)

QY	1	MetAlaLeuValArgAlaLeuValCysCysLeuLeuThrAlaTrpHisCysArgSergly	20
Db	99	ATGGCGCTGGTGCGCGCACTCGTCTGCTGCTGCTGACTGCTGCGACTGCGCTCCGGC	158
QY	21	LeuGlyLeuProValAlaProAlaGlyGlyArgAsnProProProAlaIleGlyGlnPhe	40
Db	159	CTCGGGCTGCCCGTGGCGCCCGCAGCGCGCAGGAATCCTCCTCCGGCGATAGG-----	211
QY	41	TrpHisValThrAspLeuHisLeuAspProThrTyrHisIleThrAspAspHisThrLys	60
Db	211	-----	211
QY	61	ValCysAlaSerSerLysGlyAlaAsnAlaSerAsnProGlyProPheGlyaspValLeu	80
Db	211	-----	211
QY	81	CysaspSerProTyrGlnLeuIleLeuSerAlaPheaspPheIleLysasnSerglyGln	100
Db	211	-----	211
QY	101	GluAlaSerPheMetIleTyrThrGlyaspSerProProHisValProValProGlyLeu	120
Db	212	-----GATAGCCACCTCATGTTCCTGTACCTGAACCTC	244
QY	121	SerThrAspThrValIleAsnValIleThrAsnMetThrThrThrIleGlnSerLeuPhe	140
Db	245	TCAACAGACACTGTTATTAATGTGATCACTAATATGACAACCAACCATCCAGAGTCTCTTT	304
QY	141	ProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrTrpProGlnAspGlnLeu	160
Db	305	CCAAATCTCCAGGTTTTCCTGCGCTGGGTAAATCATGACTATTGGCCACAGATCAACTG	364
QY	161	SerValValThrSerLysValTyrAsnAlaValAlaAsnLeuTrpLysProTrpLeuAsp	180

Db	365	CCTGTAGTCA	CCAGTA	AAAGTGTACA	TGCAATGCAGTAGCA	AAACCTCTGGAAACCACTAGGCTAGAT	424																
QY	181	GIUGIUA	IAIle	Ser	Thr	Leu	Arg	Lys	Gly	Gly	Phe	Tyr	Ser	Gln	Lys	Val	Thr	Thr	Asn	200			
Db	425	GAAGAAGCTAT	TAGTACTT	TTAAGGA	AAAGGTGGTTTTATTCACAGAAAGTTACAACTAAT	484																	
QY	201	Pro	Asn	Leu	Arg	Ile	Ile	Ser	Leu	Asn	Thr	Asn	Leu	Tyr	Tyr	Gly	Pro	Asn	Ile	Met	Thr	220	
Db	485	CCAAACCTTAG	GATCAT	CAGTCT	TAACACAACTGTACTACGCGCCCAATATATATGACA	544																	
QY	221	Leu	Asn	Lys	Thr	Asp	Pro	Ala	Asn	Gln	Phe	Glu	Trp	Leu	Glu	Ser	Thr	Leu	Asn	Asn	Ser	240	
Db	545	CTGACACAGA	CTGACCCAGCCAA	CCAGTTTGATGGCTAGAAAGTACATTGAACA	CACTCT	604																	
QY	241	Gln	Gln	Asn	Lys	Gln	Lys	Val	Tyr	Ile	Ile	Ala	His	Val	Pro	Val	Gly	Tyr	Leu	Pro	Ser	260	
Db	605	CAGCAGAA	TAAAGGAGGTGTATATCATAGACATGTTCCAGTGGGGTATCTGCCATCT	664																			
QY	261	Ser	Gln	Asn	Ile	Thr	Ala	Met	Arg	Glu	Tyr	Tyr	Asn	Gln	Lys	Leu	Ile	Asp	Ile	Phe	Gln	280	
Db	665	TCACAGAA	CATCACAGCAATGAGAGAACTACTATAAGAAATGTAGATATTTTCAA	724																			
QY	281	Lys	Tyr	Ser	Asp	Val	Ile	Ala	Gly	Gln	Phe	Tyr	Gly	His	Thr	His	Arg	Asp	Ser	Ile	Met	300	
Db	725	AAATACAGT	GATGTTCATTG	CAGACATTTTATGACACACACTCACAGAGACAGCATTATG	784																		
QY	301	Val	Leu	Ser	Asp	Lys	Lys	Gly	Ser	Pro	Val	Asn	Ser	Leu	Phe	Val	Ala	Pro	Ala	Val	Thr	320	
Db	785	GTTCTT	CAGATA	AAAAAGGAAGTCCAGTAAATTTCTTTGTTGTGGCTCTGCTGTTACA	844																		
QY	321	Pro	Val	Lys	Ser	Val	Leu	Gln	Lys	Gln	Thr	Asn	Asn	Pro	Gly	Ile	Arg	Leu	Phe	Gln	Tyr	340	
Db	845	CCAGTGA	AGAGTGGTTTAGAAAAACAGACCAACAATCCTGTATCAGACTGTTTCAGTAT	904																			
QY	341	Asp	Pro	Arg	Asp	Tyr	Lys	Leu	Leu	Asp	Met	Leu	Gln	Tyr	Tyr	Leu	Asn	Leu	Thr	Glu	Ala	360	
Db	905	GATCCTCGT	GATTATAATTA	TGATATGTG	CAGATTACTTGAATCTGACAGAGCG	964																	
QY	361	Asn	Leu	Lys	Gly	Glu	Ser	Ile	Trp	Lys	Leu	Glu	Ile	Tyr	Ile	Leu	Thr	Gln	Thr	Tyr	Asp	Ile	380
Db	965	AATCTAA	AGGAGAGTCCATCTGGAAGCTGGAGTATATCTGACCCAGACCTACGACATT	1024																			
QY	381	Glu	Asp	Leu	Gln	Pro	Glu	Ser	Leu	Tyr	Gly	Leu	Ala	Lys	Gln	Phe	Thr	Ile	Leu	Asp	Ser	400	
Db	1025	GAAGATT	TGACGCGGAAAGTTTATATGATTAGCTAAACAATTACATTCCTAGACAGT	1084																			
QY	401	Lys	Gln	Phe	Ile	Lys	Tyr	Tyr	Asn	Tyr	Phe	Phe	Val	Ser	Tyr	Asp	Ser	Ser	Val	Thr	Cys	420	
Db	1085	AAGCAGT	TATATAAATACTACA	CAATTACTCTCTTGTGAGTTATGACAGCAGTGTAACATGT	1144																		
QY	421	Asp	Lys	Thr	Cys	Lys	Ala	Phe	Gln	Ile	Cys	Ala	Ile	Met	Asn	Leu	Asp	Asn	Ile	Ser	Tyr	440	
Db	1145	GATAAGACAT	GTAGAGCCTTTCAGATTGTGCAATTATGAATCTTGATATAATTTCTCTAT	1204																			
QY	441	Ala	Asp	Cys	Lys	Leu	Lys	Gln	Leu	Tyr	Ile	Lys	His	Asn	Tyr	453							
Db	1205	GCAGAT	TGCCCTCAACAGCCTTATATATAAGCACAATTAC	1243																			

RESULT 13	
ABI99482	
ID	ABI99482 standard; cDNA, 1758 BP.
XX	
AC	ABI99482;
XX	
DT	07-MAR-2002 (first entry)
XX	
DE	Mouse ischaemic condition related cDNA sequence SEQ ID NO:444.
XX	
KM	Mouse; ischaemia; compressive ischaemia; occlusive ischaemia;
KM	vasospastic ischaemia; ischaemic condition; ischaemic disease; ss.
XX	
OS	Mus musculus.
XX	









Db 814 AATCTAAGGAGAGTCATCTGGAAGCTGAGTATATCTGACCAGACCTACGACATT 873  
QY 381 GIuAspLeuGlnProGluSerLeuTyrGlyLeuAlaIysGlnPheThrIleLeuAspSer 400  
Db 874 GAAGATTTCAGCCGGAAGTTATATGATGATGACTTAACAATTACATCTAGACAGT 933  
QY 401 LysGlnPheIleIleTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCys 420  
Db 934 AAGCAGTTTATAAATACTACAATTACTCTTGTGAGTTATGACAGCAGTGAACATGT 993  
QY 421 AspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTyr 440  
Db 994 GATTAAGACATGTAAGGCTTTCAGATTGTGCAATTATGAATCTTGATAATATTTCTTAT 1053  
QY 441 AlaAspCysLeuLysGlnLeuTyrIleLysHisAsnTyr 453  
Db 1054 GCAGATTGCCCTCAACAGCTTATATATAAGCACAAATTAC 1092

RESULT 15

AAA02374  
ID AAA02374 standard; cDNA; 728 BP.

XX AC AAA02374;

XX DT 19-MAY-2000 (first entry)

XX DE Human colon cancer cell line polynucleotide sequence SEQ ID NO:2365.

XX KM Human; colon cancer; tumour; diagnosis; gene expression product; probe;

KW detection; cancerous state; metastasis; identification; breast cancer;

KM oestrogen receptor-positive breast cancer; therapy;

KW oestrogen receptor-negative breast cancer; lung cancer; ss.

XX OS Homo sapiens.

XX PN WO9958675-A2.

XX PD 18-NOV-1999.

XX PF 13-MAY-1999; 99WO-US010602.

XX PR 14-MAY-1998; 98US-0085426P.

XX PR 15-MAY-1998; 98US-0085537P.

XX PR 15-MAY-1998; 98US-0085696P.

XX PR 21-OCT-1998; 98US-0105234P.

XX PR 27-OCT-1998; 98US-0105877P.

XX PA (CHIR ) CHIRON CORP.

XX PA (HYSE-) HYSEQ INC.

XX PI Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;

XX PI Reinhard C, Giese K, Randazzo F, Kennedy GC, Pot D, Kaasam A;

XX PI Lamson G, Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;

XX PI Leshkowitz D, Kita D, Garcia V, Jones LW, Stache-Crain B;

XX DR WPI; 2000-126369/11.

XX PT Polynucleotide library used to determine cancerous states of mammalian

XX PT cells.

XX PS Claim 1; Page 940; 1097BP; English.

XX CC AAA00010 to AAA02716 represent polynucleotides isolated from cDNA

CC libraries constructed from human colon cancer cell lines. The present

CC invention also describes a method of detecting differentially expressed

CC genes correlated with a cancerous state of a mammalian cell, comprising

CC detecting at least one differentially expressed gene product in a test

CC sample derived from a cell suspected of being cancerous, where detection

CC of the differentially expressed gene product is correlated with a

CC cancerous state of the cell from which the test sample was derived. The

CC polynucleotides sequences can be used in a method for detecting

CC differentially expressed genes correlated with a cancerous state of a

CC mammalian cell. The polynucleotides can also be used as probes for

CC detecting and mapping related genes. They can be used in diagnosis and

CC prognosis of diseases and disorders (e.g. identification of pre-

CC metastatic or metastatic cancerous states, stages of cancer, or

CC responsiveness of cancer to therapy). This is particularly for breast

CC cancer, oestrogen receptor-positive breast cancer, oestrogen receptor-

CC negative breast cancer, lung cancer, and colon cancer

XX SQ Sequence 728 BP; 240 A; 155 C; 139 G; 189 T; 0 U; 5 Other;

Alignment Scores:

Pred. No.: 4.9e-107 Length: 728

Score: 1209.00 Matches: 230

Percent Similarity: 98.71% Conservative: 0

Best Local Similarity: 98.71% Mismatches: 3

Query Match: 49.81% Indels: 0

DB: 3 Gaps: 0

US-09-823-119B-1 (1-453) x AAA02374 (1-728)

QY 110 AspSerProPheHisValProValProGluLeuSerThrAspThrValIleAsnValIle 129

Db 28 GATAGCCACCTCATGTCTCTGTAACCTGAACCTCAACAGACACACTGTTAATAATGTGATC 87

QY 130 ThrAsnMetThrThrThrIleGlnSerLeuPheProAsnLeuGlnValPheProAlaLeu 149

Db 88 ACTAATATGACAAACCACTCCAGAGTCTTCCAAATCTCCAGGTTTCCCTGCGCTG 147

QY 150 GlysAsnHisAspTyrTrpProGlnAspGlnLeuSerValThrSerLysValTyrAsn 169

Db 148 GGTATATCATGACTATTGGCCACAGATCATCTGCTAGTCAACCAAGTAAGTACAAT 207

QY 170 AlaValAlaAsnLeuTrpLysProTrpLeuAspGluAlaIleSerThrLeuArgLys 189

Db 208 GCAGTAGCAACCTCTGGAACCATGGCTAGATGAAGAAGCTATTAGTACTTTAAGGAA 267

QY 190 GlyGlyPheTyrSerGlnLysValThrThrAsnProAsnLeuArgIleIleSerLeuAsn 209

Db 268 GGTGTTTATTATTCACAGAAAGTTACACTAATCCAAACCTTAGATCATCTTAAC 327

QY 210 ThrAsnLeuTyrTyrGlyProAsnIleMetThrLeuAsnLysThrAspProAlaAsnGln 229

Db 328 ACAAACTGTACTACGCGCCAAATATATGACACTGAACAAAGACTGACCAACCAACAG 387

QY 230 PheGluTrpLeuGlnSerThrLeuAsnAsnSerGlnGlnAsnLysGlnLysValTyrIle 249

Db 388 TTTGAATGGCTAGAAAGTACATTGAACAACCTCAGCAGAATAAGGAAGGTATATC 447

QY 250 IleAlaHisValProValGlyTyrLeuProSerSerGlnAsnIleThrAlaMetArgGlu 269

Db 448 ATAGCACATGTTCCAGTGGGTATCTGCCATCTTCACAGAACATCAGCAATGAGAGAA 507

QY 270 TyrTyrAsnGlnLysLeuIleAspIlePheGlnLysTyrSerAspValIleAlaGlyGln 289

Db 508 TACTATATGAGAAATTGATAGATATTTTCAAAAATACAGTGTATGTCATTTGACAGACAA 567

QY 290 PheTyrGlyHisThrHisArgAspSerIleMetValLeuSerAspLysLysGlySerPro 309

Db 568 TTTATGACACACTCACAGAGACAGCAATTAGGTTCTTCAGATATAAAGGAAGTCCA 627

QY 310 ValAsnSerLeuPheValAlaProAlaValThrProValLysSerValLeuGlnLysGln 329

Db 628 GTAATTTCTTTGTTGTGGCTCTGCTGTTACACCAAGTAAGAGTGTTTAGAAAAACAG 687

QY 330 ThrAsnAsnProGlyIleArgLeuPheGlnTyrAspPro 342

Db 688 ACCAACAAATNCTGTATCAGACTGTTCAAGTATGATCCT 726

Search completed: April 5, 2005, 13:24:41  
Job time : 654 secs

**THIS PAGE BLANK (USPTO)**